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Introduction
With an annual incidence of about 4 to 9 per million in the United States of America 
and European countries, uveal melanoma (UM) is a rather rare malignant disease entity 
[1]. UM can arise in any part of the uveal tract, that is in the iris, ciliary body and/or 
choroid. Iris melanomas are extremely uncommon and have a different nature as well 
as treatment approach. This thesis will only relate UM to choroidal and ciliary body 
melanomas, which take up 95% of all UM. Most the patients are diagnosed with UM 
because of having (mild) visual symptoms, such as blurred and/or declined vision, 
light flashes, metamorphopsia (change in shape of an object) and floaters (“floating 
flies”). Although effective local treatment options for the primary tumor, are available, a 
substantial part of the patients eventually die from metastatic disease. UM metastasize 
haematogenously, mainly to the liver. The diagnosis of metastatic uveal melanoma 
disease is often several years after the primary treatment, with a median of 4 to 6 years. 
Once (liver) metastases have been diagnosed, the prognosis is infaust in almost all 
cases with a mean survival of 3 to 9 months.
In 1978 Zimmerman, McLean and Foster suggested that enucleation, which was 
historically the gold standard treatment option, could possibly accelerate the 
dissemination of tumor cells, noting the abrupt rise of mortality rates two to three 
years post-enucleation[2]. This was the incentive to the development of eye sparing 
treatment modalities. Although they did not lead to better metastatic free survival 
rates, these modalities have taken an important place in the treatment of UM nowadays, 
because of advantages of the treatment, such as preservation of the affected eye and 
maintenance of a usable vision [3, 4].
Radiation therapy of choroideal melanomas was initiated in 1930 by Moore [5], who 
used radon seeds. Modern techniques of brachytherapy involve a shielded plaque 
containing radioactive isotopes, sutured to the sclera. Meanwhile, brachytherapy 
has proven to be a good alternative for enucleation with excellent local control rates, 
especially for small and medium sized tumors [6] [7-11]. Heavy particle irradiation is 
used to treat medium sized and large UM [12-17]. Nowadays, UM has become one of 
the accepted indications for treatment with heavy particles. The advantage of this 
technique is the precise dose delivery and the rapid dose fall off due to the Bragg peak 
characteristics. Moreover, there is no maximum limit regarding the tumor thickness. 
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Both the size and the location of these (often large sized) UM make these tumors highly 
suitable for this type of irradiation. The results in terms of local control have proven 
to be very good, with local control rates above the 90 percent [14-21]. However, the 
secondary enucleation rate due to toxicity or local failure is still substantial, i.e. 6 to 25 
percent [12, 17, 18]. This is mainly caused by the appearance of neovascular glaucoma.
Treatment by heavy particle accelerators are extremely costly, and consequently, the 
facilities for this type of treatment are scarce. Fortunately, currently there are new 
initiatives, also in the Netherlands. Photon accelerators, on the other hand are widely 
available and cost-effective. It is therefore appropriate to find out whether UM could 
be irradiated with photons. That is, with a control rate comparable to protons and a 
very low complication probability. The eye consists of (surrounding) healthy structures 
which are very sensitive to radiation. The advent of precise irradiation techniques, 
such as stereotactic radiation therapy (SRT), make it possible to irradiate the tumour 
and spare the surrounding tissue to a great extent [22-29] [30, 31]. For UM a radio 
surgical technique (single fraction SRT) has been introduced in 1987 with good results 
regarding local control. However, the number of significant radiation induced adverse 
reactions was high (13 out of 14 patients) [24]. By fractionating the dose, normal tissue 
can be spared even more. 
The aim of this thesis is to describe an accurate and reproducible method for the 
fractionated stereotactic treatment (fSRT) of uveal melanoma and to investigate its 
safety, efficacy, and complications in short term and long term follow-up. This chapter 
presents an overview of the problems at stake. A number of relevant aspects with 
respect to fSRT of UM are described in the following chapters (2-6):
Prerequisite of fSRT is the accurate reproducibility of the position of the tumor during 
treatment. In chapter 2 the development of a non-invasive, reliable, patient friendly 
relocatable stereotactic frame with an eye fixation module for irradiation of eye 
melanoma is described. Also, the repositioning accuracy of this relocatable frame was 
evaluated.
In chapter 3 early data on the effectiveness and acute side effects of fSRT for uveal 
melanoma are reported.
The local control at long term, late side effects and survival of uveal melanoma patients 
treated with fSRT are reported in chapter 4.
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Irradiation of the lacrimal gland can result in atrophy causing reduced tear production 
and consequently, a dry eye. When applied to the whole organ, a clear dose effect 
relationship has been established. Using conformal irradiation techniques such as fSRT, 
the surrounding tissues such as the lacrimal gland can be partly spared. chapter 5 
describes the analysis of a dose volume effect for (inhomogeneous) irradiated lacrimal 
glands.
In ocular oncology centers more than one treatment facilitity is available and the choice 
for treatment is made based on the clinical history, ophthalmic examination and tumor 
data. However, for a substantial part of medium sized UM different treatment options 
are available. Beside enucleation, medium sized UM could be treated with different 
radiation modalities, i.e. brachytherapy, fSRT and proton therapy. Out of literature, 
it is difficult to compare the outcomes of these modalities, since most publications 
are based upon retrospective studies. Moreover, comparative survival studies of 
brachytherapy versus SRT have not been published yet. In chapter 6 we studied 
overall survival, metastatic-free survival and secondary enucleation rate of choroidal 
melanomas treated with Ruthenium brachytherapy (Ru-106) versus stereotactic 
radiotherapy (fSRT) of patients with interchangeable characteristics. The main goal of 
our study was to determine the differences in clinical and survival outcome comparing 
Ru-106 and SRT for UM of comparable dimensions.
In chapter 7, a summary of the relevant publications is listed. Also future perspectives 
are discussed.
Introduction and outline of the thesis 11
References
1. Singh, AD, Topham, A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 
2003;110:956-961.
2. Zimmerman, LE, McLean, IW, Foster, WD. Does enucleation of the eye containing a malignant 
melanoma prevent or accelerate the dissemination of tumour cells. Br J Ophthalmol 1978;62:420-425.
3. Singh, AD, Rennie, IG, Kivela, T, Seregard, S, Grossniklaus, H. The Zimmerman-McLean-Foster 
hypothesis: 25 years later. Br J Ophthalmol 2004;88:962-967.
4. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year 
mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006;124:1684-1693.
5. Moore, RF. Choroidal Sarcoma Treated by the Intraocular Insertion of Radon Seeds. Br J Ophthalmol 
1930;14:145-152.
6. Verschueren, KM, Creutzberg, CL, Schalij-Delfos, NE, et al. Long-term outcomes of eye-conserving 
treatment with Ruthenium(106) brachytherapy for choroidal melanoma. Radiother Oncol;95:332-338.
7. Krohn, J, Monge, OR, Skorpen, TN, Mork, SJ, Dahl, O. Posterior uveal melanoma treated with I-125 
brachytherapy or primary enucleation. Eye 2008;22:1398-1403.
8. Bergman, L, Nilsson, B, Lundell, G, Lundell, M, Seregard, S. Ruthenium brachytherapy for uveal 
melanoma, 1979-2003: survival and functional outcomes in the Swedish population. Ophthalmology 
2005;112:834-840.
9. Lommatzsch, PK, Werschnik, C, Schuster, E. Long-term follow-up of Ru-106/Rh-106 brachytherapy for 
posterior uveal melanoma. Graefes Arch Clin Exp Ophthalmol 2000;238:129-137.
10. Freire, JE, De Potter, P, Brady, LW, Longton, WA. Brachytherapy in primary ocular tumors. Semin Surg 
Oncol 1997;13:167-176.
11. Melia, BM, Abramson, DH, Albert, DM, et al. Collaborative ocular melanoma study (COMS) randomized 
trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report 
no. 16. Ophthalmology 2001;108:348-366.
12. Dendale, R, Lumbroso-Le Rouic, L, Noel, G, et al. Proton beam radiotherapy for uveal melanoma: 
results of Curie Institut-Orsay proton therapy center (ICPO). Int J Radiat Oncol Biol Phys 2006;65:780-
787.
13. Conway, RM, Poothullil, AM, Daftari, IK, Weinberg, V, Chung, JE, O’Brien, JM. Estimates of ocular and 
visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy. 
Arch Ophthalmol 2006;124:838-843.
14. Gragoudas, ES, Marie Lane, A. Uveal melanoma: proton beam irradiation. Ophthalmol Clin North Am 
2005;18:111-118, ix.
15. Kodjikian, L, Roy, P, Rouberol, F, et al. Survival after proton-beam irradiation of uveal melanomas. Am J 
Ophthalmol 2004;137:1002-1010.
16. Gragoudas, ES, Lane, AM, Munzenrider, J, Egan, KM, Li, W. Long-term risk of local failure after proton 
therapy for choroidal/ciliary body melanoma. Trans Am Ophthalmol Soc 2002;100:43-48; discussion 
48-49.
17. Fuss, M, Loredo, LN, Blacharski, PA, Grove, RI, Slater, JD. Proton radiation therapy for medium and 
large choroidal melanoma: preservation of the eye and its functionality. Int J Radiat Oncol Biol Phys 
2001;49:1053-1059.
18. Gragoudas, ES, Seddon, JM, Egan, K, et al. Long-term results of proton beam irradiated uveal 
melanomas. Ophthalmology 1987;94:349-353.
19. Wilson, MW, Hungerford, JL. Comparison of episcleral plaque and proton beam radiation therapy for 
the treatment of choroidal melanoma. Ophthalmology 1999;106:1579-1587.
20. Egger, E, Schalenbourg, A, Zografos, L, et al. Maximizing local tumor control and survival after proton 
beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys 2001;51:138-147.
21. Damato, B. Developments in the management of uveal melanoma. Clin Experiment Ophthalmol 
2004;32:639-647.
Chapter 112
22. Marchini, G, Babighian, S, Tomazzoli, L, et al. Stereotactic radiosurgery of uveal melanomas: preliminary 
results with Gamma Knife treatment. Stereotact Funct Neurosurg 1995;64:72-79.
23. Marchini, G, Gerosa, M, Piovan, E, et al. Gamma Knife stereotactic radiosurgery for uveal melanoma: 
clinical results after 2 years. Stereotact Funct Neurosurg 1996;66:208-213.
24. Rennie, I, Forster, D, Kemeny, A, Walton, L, Kunkler, I. The use of single fraction Leksell stereotactic 
radiosurgery in the treatment of uveal melanoma. Acta Ophthalmol Scand 1996;74:558-562.
25. Tokuuye, K, Sumi, M, Kagami, Y, et al. Long-term observations of a patient with choroidal melanoma 
following fractionated stereotactic radiotherapy: a case report. Acta Ophthalmol Scand 2000;78:477-
479.
26. Zehetmayer, M, Kitz, K, Menapace, R, et al. Local tumor control and morbidity after one to three 
fractions of stereotactic external beam irradiation for uveal melanoma. Radiother Oncol 2000;55:135-
144.
27. Dieckmann, K, Georg, D, Zehetmayer, M, Bogner, J, Georgopoulos, M, Potter, R. LINAC based stereotactic 
radiotherapy of uveal melanoma: 4 years clinical experience. Radiother Oncol 2003;67:199-206.
28. Fakiris, AJ, Lo, SS, Henderson, MA, et al. Gamma-knife-based stereotactic radiosurgery for uveal 
melanoma. Stereotact Funct Neurosurg 2007;85:106-112.
29. Modorati, G, Miserocchi, E, Galli, L, Picozzi, P, Rama, P. Gamma knife radiosurgery for uveal melanoma: 
12 years of experience. Br J Ophthalmol 2009;93:40-44.
30. Furdova, A, Slezak, P, Chorvath, M, Waczulikova, I, Sramka, M, Kralik, G. No differences in outcome 
between radical surgical treatment (enucleation) and stereotactic radiosurgery in patients with 
posterior uveal melanoma. Neoplasma;57:377-381.
31. Toktas, ZO, Bicer, A, Demirci, G, et al. Gamma knife stereotactic radiosurgery yields good long-
term outcomes for low-volume uveal melanomas without intraocular complications. J Clin 
Neurosci;17:441-445.
13
Karin Muller, M.D.1,*, Peter J.C.M. Nowak, M.D., PH.D.1, 
Grégorius P.M. Luyten, M.D., PH.D.2, Johannes P. Marijnissen, PH.D.1, 
Connie de Pan1 and Peter Levendag, PH.D.1
Departments of Radiation-Oncology1 and Ophthalmology2, 
Erasmus Medical Center, Rotterdam, The Netherlands
International Journal of Radiation Oncology, Biology and Physics 2004;58(1):284-91 
Chapter 214
Abstract
Purpose 
To describe a reliable, patient friendly relocatable stereotactic frame for irradiation of 
eye melanoma and to evaluate the repositioning accuracy of the stereotactic treatment.
Methods and materials 
An extra construction with a blinking light and a camera is attached to a non-invasive 
relocatable Gill Thomas Cosman stereotactic frame. The position of the blinking light 
is in front of the unaffected eye and can be adjusted to achieve an optimal position for 
irradiation. The position of the diseased eye is monitored with a small camera. A planning 
CT scan is performed with the affected eye in treatment position and is matched with 
a MR scan in order to improve the accuracy of the delineation of the tumor. Both the 
translation and rotation of the affected eye are calculated by comparing the planning 
CT scan with a control CT scan, performed after the radiation therapy is completed.
Results 
Nineteen irradiated eye melanoma patients were analyzed. All patients received 5 
fractions of 10 Gy within 5 days. The DCH (depth-confirmation helmet) measurements 
of the day-to-day treatment position of the skull within the GTC frame were analyzed 
in anteroposterior, lateral and vertical direction and were 0.1±0.3, 0.0±0.2 and 0.2±0.2 
mm (mean±sd), respectively. The average of translations of the eye on the planning and 
control CT scan were 0.1±0.3 mm, 0.1± 0.4 and 0.1±0.5 mm, respectively. The median 
rotation of the diseased eye was 8.3 degrees.
Conclusions 
The described Rotterdam eye fixation system turned out to be a feasible, reliable and 
patient-friendly system. 
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Introduction
In adults melanoma is the most common malignancy of the eye and arises from 
the uvea, formed by the choroid, ciliary body and iris. Uveal melanomas have 
traditionally been treated by enucleation. Other treatment options use radiotherapy 
with or without transpupillar thermotherapy. Recent comparative studies showed no 
difference in survival between enucleation and Co-60 plaque radiation therapy 1 or 
I-125 brachytherapy 2. Thus, brachytherapy appears to be a useful alternative for the 
treatment of small uveal melanoma. Proton and Helium radiation techniques are also 
widely used, particularly in medium sized tumors 3-9. 
Radiosurgery (a high radiation dose in 1 (to 3) fractions) of eye melanoma began in 
1987 using the Gamma Knife, with as major advantage the very precise delivery of 
dose to the tumor 10-13. Local control rates of 93% to 98% were achieved. Due to the 
high single dose, the most important disadvantage of radiosurgery is the loss of 
radiobiological sparing if critical structures are adjacent to the tumor, resulting in an 
enhanced complication probability 10, 13-15. Moreover, the invasive frame as applied with 
radiosurgery is rather uncomfortable for patients and not suitable in case of fractionated 
treatment schemes. Fractionated stereotactic radiotherapy (fr. SRT) with a relocatable 
frame allows for delivery of an equivalent effective dose to the tumor combined with 
reduced effective dose in the surrounding tissues. The relocatable frame being non-
invasive is also more convenient for patients. Finally, the repositioning accuracy (RA) of 
the relocatable stereotactic frame has shown to be sufficient 16. However, the RA of the 
relocatable stereotactic frame does not imply the immobilization of eye movements. 
Fixation of the affected eye in a specified position can contribute to an even better 
sparing of critical structures. Several eye fixation methods have been developed, each 
with its specific disadvantages.
The ultimate challenge remains to design a method for fixation of the affected eye in 
a favourable treatment position during the whole course of fr. SRT of eye melanoma. 
The aim of this paper is to describe a patient friendly eye fixation device, attached on a 
relocatable stereotactic frame for eye melanoma patients and to analyze the RA of the 
target volume. 
Chapter 216
Methods and Materials
The eye melanoma stereotactic frame
For the purpose of stereotactic irradiation of eye melanoma the Gill Thomass Cosman 
frame (GTC frame™, Radionics, Burlington, USA) was modified 16, 17.
To immobilize the affected eye during the planning CT scan procedure and during the 
stereotactic irradiation in the intended treatment position, we used a plastic (PVC™) 
eye fixation device attached to the GTC frame, which contains both a blinking light 
and a camera (figure 1). The blinking light (fibre-glass connected to LED) is positioned 
in front of the healthy eye at a distance of 20 cm and its location can be changed in 
horizontal and vertical direction. The patient is asked to gaze at the blinking light. The 
position of the blinking light is adjusted to each individual patient in order to achieve 
an optimal angle of view; a small rotation of the eye-ball and tumor may improve 
tumor coverage and reduce the exposure to critical surrounding structures. A small 
camera, also fixed at the PVC attachment, is positioned at a distance of 20 cm from the 
affected eye to verify the position of the eye (i.e. the angle of view) by checking the 
circumference of the iris and pupil, drawn on an overhead sheet at the monitor screen 
(figure 2). In order to quantify the rotation of the eye, a scale strip is recorded by the 
camera and contoured on the sheet. 
Patients
Twenty-three patients were treated with fr. SRT between 1999 and 2002. Of each patient 
a planning CT scan and a control CT scan (after treatment) were made. Four patients 
had to be excluded: two control scans could not be analyzed for technical reasons 
and of a third patient the localizer frame was not placed on the GTC frame during the 
control scan. One patient did not look at the blinking light during the second CT scan 
(after completion of the radiotherapy series). Of the remaining nineteen patients, both 
the planning and control CT scan were available for evaluation of the modified frame 
and analysis of the repositioning accuracy.
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FigUre 1  Relocatable stereotactic eye melanoma frame
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FigUre 2  Example of monitored eye; the contours of iris, pupil, eyelids and scale strip are drawn 
on the screen of the monitor and are used during radiation.
Planning and treatment
MRI scan
Preceding treatment planning, a MRI scan (1,5 Tesla; axial and sagital T1w SE 3 mm-
slices, and occasionally axial T2w TSE 3mm- slices) is made of the orbit of the affected 
eye. 
Planning CT scan
Two planning CT scans are performed (AcQSim, Philips™) with the localizer frame 
positioned on the GTC frame. The first scan is made of the whole skull. A second scan 
with contrast (Omnipaque®) at the level of the eyes is performed with the affected eye 
in treatment position recorded by the camera (1.5-mm slices with an index of 1 mm). 
From the second scan, two fields of view are reconstructed: one containing the rods of 
the localizer frame, the second reconstruction enclosing the orbit of the diseased eye. 
The sizes and centers of the fields of view are recorded. 
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Contouring
The CT scan of the orbit is matched with the MRI-scan in order to improve the accuracy 
of delineation of the GTV, using ImageFusion™ Version 2.02 (Radionics). The primary 
lesion is contoured on both the CT scan and the fused MRI. The GTV encloses the 
primary lesion contoured on CT, corrected for any extension of the visible lesion as 
observed on MRI, and taking into account the findings of ultrasound imaging and 
fundus photography. Besides the GTV, the critical structures are also contoured on 
CT, i.e. the optic nerves and the lens with ciliary body of the affected eye and the 
contralateral eye. The contours are transferred into the whole skull CT scan using an 
in-house developed software program.
Planning
The PTV is constructed by adding a 3 dimensional margin of 2 mm to the GTV. A treatment 
plan is made using stereotactic arcs of 6 MV photons (XKnife RT™ 1.03, Radionics), with 
one or more isocenters. A total dose of 50 Gy in 5 fractions is prescribed to the 80 % 
isodose surface, encompassing the PTV. Doses of 4 Gy per fraction in the optic nerve 
and 2.5 Gy per fraction to one-fourth of the lens and ciliary body are considered to be 
acceptable. An example of treatment planning is shown in figure 3. 
FigUre 3  Example of treatment planning; the eye, GTV, PTV, lens, ciliary body and optic nerve 
are contoured. The isodose lines presented are 10, 4 and 2.5 Gy per fraction.
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Treatment
The total dose is delivered on 5 consecutive days, i.e. Monday to Friday. Before 
each treatment the position of the skull within the GTC frame is checked by DCH 
measurements. Retrospectively, the data of these measurements are analyzed with 
a spreadsheet program (Excel™), designed for this purpose. The DCH measurements 
were split into a displacement in anteroposterior (AP), lateral and vertical direction. 
The position and movements of the diseased eye are monitored with the on-line video 
camera. If the eye moves more than 2 mm with regard to the initial drawing of the eye 
and lens, the irradiation is interrupted and the patient is instructed to gaze at the light 
again.
Verification of the fixation of the eye
After the last fraction, a second CT scan in treatment position is performed. The eye and 
lens are delineated on the planning and control CT scan by the same clinician.  
Differences in eye position, relative to the localizer frame, can be described in 
translations and rotations of the eye-ball. Since the tumor is not always clearly visible 
on CT, its coordinates could not be used reliably for calculation of the rotation. 
However, the distance between the tumor and the center of the eye is approximately 
the distance between the lens and the center of the eye. Therefore, for determination of 
the rotation, both the coordinates of the eye and the lens are used as depicted in figure 
4. The translation of the eye is defined as the shift of the center of the eye on the CT 
scans. The coordinates of the lens of the second scan are corrected for the translation 
of the eye (depicted by vector n). The distance between the coordinates of the lens and 
the eye of the planning scan is called vector p; vector q is the distance between the 
corrected coordinates of the lens of the second scan and the coordinates of the lens 
of the planning scan. The rotation of the eye is defined by the angle (α) between the 
vectors of the center of the eye to the center of the lens on planning CT scan and to the 
center of the lens on the control CT scan, corrected for the translation of the eye (i.e. 
the angle between vector p and q), using equation 1:
α = 2 ∙ sin-1(q/2p)  (1)
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FigUre 4  Schematic view of rotation calculations; the contours of the control scan are striped; 
the center of the lens of the control CT scan is corrected for the translation of the eye (n). The 
translation of the lens (q) is calculated by subtracting the coordinates of the corrected center of 
the lens from the coordinates of the center of the lens on the planning CT scan; p is the distance 
between the center of the eye and the center of the lens. The angle of rotation is depicted by α.
Statistical analysis
Since the results of the translation did not show a normal distribution, the mean and 
standard deviation are of limited value. Instead, we used the median and range for our 
analysis. For the range, the maximum and minimum of all results were used. A possible 
correlation between gaze direction of the eye and the deviation of rotation was tested 
using the Spearman’s test.
As stated, the DCH measurements were split into displacements in anteroposterior 
(AP), lateral (LAT) and vertical (VERT) direction. The means of the AP, lateral and vertical 
displacements of a particular fraction are considered to be the estimate of the shift in 
this direction. The mean of these values of all fractions is the systematic error, while the 
random error is the standard deviation of the variations of the shifts.
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Results
Tumor data
All 19 patients received 5 fractions of 10 Gy on the primary lesion. The general data of 
this group is pointed out in Table1. 
table 1  General Data
characteristics Mean Sd na
Age (years) 61 10
Size (mm)
Diameter
Horizontal 10.8 2.6
Vertical 9.6 2.6
Prominence 5.4 2.1
Site
Nasal 6
Central 7
Temporal 6
a Total number of patients is 19
Depth-Confirmation Helmet Measurements
The results of the DCH measurement are summarized in Table 2. The systematic errors 
are 0.1±0.3, 0.0±0.2 and 0.2±0.2 mm, in anteroposterior, lateral and vertical direction, 
respectively. The mean random (i.e. daily) displacements are 0.4, 0.5 and 0.4 mm, 
respectively.
table 2  Depth-Confirmation Helmet measurements (Planning CT and daily measurements)
Systematic error a
(mm)
random error b
(mm)
range
(mm)
AP 0.1 ± 0.3 0.4 -0.7 – 1.4
LAT 0.0 ± 0.2 0.5 -1.0 – 1.0
VERT 0.2 ± 0.2 0.4 -0.2 – 0.9
a The systematic error is the mean of the mean shift of all patients (plus standard deviation)
b The random error is the standard deviation of the variations of the shifts
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Comparison of CT scans
The mean errors of the DCH-measurements between the planning and control CT scans 
were 0.1±0.3 mm, 0.1± 0.4 and 0.1±0.5 mm for the AP, lateral and vertical direction, 
respectively.
The results of the translation of the eye and lens are presented in Table 3. The median 
translation of the eye was 0.5, 0.3 and 1.2 mm (in AP, lateral and vertical direction, 
respectively), with a range of 4.5 mm.
The median rotation of the eye was 8 degrees, with an inter-patient range of 22 degrees 
(Figure 5).
FigUre 5  Rotation of the eye per patient. The bars indicate the rotation of each patient; the 
dotted line is the maximum allowed rotation (see text).
Although a comfortable gaze direction (straightforward) for each patient is the first 
intention, sometimes a forced gaze direction is required to spare critical structures. No 
statistical correlation between the rotation lens and angle of view direction was found 
(Figure 6).
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FigUre 6  Correlation view direction and magnitude of deviation of rotation; the correlation of 
the gaze direction of the eye and the deviation of rotation was tested using the Spearman’s test. 
a. Lateral direction; Spearman’s rho of 0.098 (p=0.69) 
b. Vertical direction; Spearman’s rho of 0.397 (p=0.09)
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Discussion
The clinical outcome of enucleation has been studied by several investigators 18-22. It 
was suggested that there could be an enhanced dissemination of tumor cells caused 
by enucleation. Various eye sparing treatment modalities have been developed with 
the main goal of leaving the affected eye unimpaired with an optimal sparing of the 
visual function.
Stereotactic radiation therapy has proven to be a useful treatment modality for small, 
well localized tumors among which brain tumors, because of a very precise dose delivery 
with a rapid dose fall-off. In this respect, the design of immobilization techniques to 
fixate the position of the diseased eye has become of paramount importance. Since the 
introduction of eye sparing external beam radiation therapy in eye melanoma patients, 
several eye fixation methods have been described. In proton beam irradiation, patients 
were asked to focus on a light, while the gaze direction of the eye was checked by 
the position of the radiopaque tantalum rings on a film 8, 9. Gragoudas et al. described 
a voluntary fixation of the eye that could be controlled throughout the procedure 
by monitoring the eye using a television system 23. Using helium ion radiotherapy, 
Castro et al. described a technique in which the fixated eye was checked by close-up 
monitoring by a camera 3.
Zehetmayer et al. described a suction fixation method for radiosurgical treatment 
of eye melanomas 24-26. After retrobulbar anaesthesia, a circular vacuum chamber 
fixes the eye, similar to fixation techniques used for corneal surgical procedures. The 
vacuum chamber is linked to the stereotactic frame. In patients treated by Mueller et al. 
complete akinesia of the eye was achieved by retrobulbar anaesthesia 11, 27. Langmann 
et al. anaesthetized the insertions of the four rectus muscles transconjunctivally, by a 
retrobulbar anaesthetic block. 12. 
Being invasive, these accurate fixation systems, however, are not ideal for fractionated 
stereotactic radiation therapy. Moreover, a non-invasive fixation system is more 
comfortable for patients. Only few authors describe an eye fixation method for fr. SRT 
28-30. Bellmann et al. described a method in which patients are instructed to look at a 
fixation point with their diseased eye 30. Since most patients have a declined visibility 
due to the tumor and because of the conjugated eye movements, it seems more 
reliable to make use of the vision of the healthy, while monitoring the movements 
of the diseased eye. In the immobilization technique described by Dieckman et al. 28, 
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the fixation point is not movable, so patients have to look straight forward. Since in 
some instances a different direction of the eye can result in more sparing of critical 
structures, a non-movable fixation point does have implicit limitations. Moreover, the 
RA was only analyzed using the eye movements as monitored by the camera. This is less 
suitable, because of the lack of a reliable reference point, since the camera could move 
as well. Tokuuye et al. used no stereotactic frame 29. Patients were simply instructed to 
look forward; a plastic head mould supported the eye fixation. 
The eye fixation system for fr. SRT presented in this paper has an adjustable fixation light 
placed in front of the healthy eye, so that the gaze direction of the eyes can be changed 
in order to get an optimal position of both the target and critical structures for optimal 
irradiation. The position of the diseased eye is monitored during CT scanning as well 
as during treatment. Displacements of the eye relative to the contour on the monitor 
screen at the time of radiotherapy can be due to either a shift of the head in the GTC 
frame (although within the allowed 2 mm) or the rotation of the eyes. To minimize the 
effect of the shift of the head, the fixation light as well as the camera is positioned as far 
from the eyes as possible. The distance is limited due the size of the gantry aperture of 
the CT scan and the rigidity of the material used for fixation. The daily set-up deviations 
are acquired by the use of DCH measurements, which yield a day-to-day deviation of 
the head position inside the GTC frame. The variations are comparable with previously 
reported results of repositioning accuracy of the GTC frame in literature 16, 17. The results 
of DCH measurements are comparable to the CT scan measurements and are clearly 
within the error permitted during treatment, i.e. the median translation of the eye was 
0.5, 0.3 and 1.2 mm in AP, lateral and vertical direction, respectively. However, the range 
of the translation was considerable (Table 3). One patient showed unexplainable large 
deviations of more than 2 mm.
The consequences of the eye movements on the accuracy of irradiation of the tumor 
were calculated. Since the mean distance between the center of the eye and the center 
of the GTV is 9.5 mm, a rotation of 12 degrees will result in a shift of 2 mm (which is the 
GTV-PTV margin). Two patients had rotations larger than 12 degrees (Figure 5). 
The method of the individual adjusted fixation light is feasible, since there was no 
correlation between the gaze direction and the magnitude of rotation deviation. 
Improvements of the Rotterdam eye fixation system with respect to rigidity and MRI 
compatibility are warranted. Furthermore, a reliable QA device for the eye fixation 
system is in development. 
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table 3  Results Translation (mm)
eye lens
Median range Median range
AP 0.5 (0.1 – 1.8) 0.4 (0.0 – 1.6)
LAT 0.3 (0.0 – 4.5) 0.4 (0.1 – 5.3)
VERT 1.2 (0.0 – 3.9) 0.6 (0.1 – 2.8)
Conclusion
The Rotterdam eye fixation system appeared feasible and reliable and is very patient-
friendly. Some improvements of the frame are warranted. 
The daily DCH-measurements combined with the eye fixation are sufficient RA check-
up for treatment.
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Abstract
Purpose
To study the effectiveness and acute side effects of fractionated Stereotactic Radiation 
Therapy (fSRT) for uveal melanoma.
Methods and Materials
Between 1999 and 2003, 38 patients (21 male, 17 female) were included in a prospective, 
nonrandomized clinical trial (mean FU of 25 months). A total dose of 50 Gy was given 
in 5 consecutive days. A blinking light and a camera (to monitor the position of the 
diseased eye) were fixed to a non-invasive relocatable stereotactic frame. Primary 
endpoints were local control, best corrected visual acuity (BCVA) and toxicity at 3, 6, 12 
and 24 months, respectively.
Results
After 3 months (38 patients) the local control was 100%, after 12 months (32 patients) 
and 24 months (15 patients) no recurrences were seen. The BCVA declined from a mean 
of 0.21 at diagnosis to 0.06 two years after therapy. The acute side effects after 3 months 
were: conjunctival symptoms (10), loss of lashes or hair (6), visual symptoms (5), fatigue 
(5), dry eye (1), cataract (1), and pain (4). One eye was enucleated at 2 months after fSRT.
Conclusions
Preliminary results demonstrate that fSRT is an effective and safe treatment modality for 
uveal melanoma with an excellent local control and mild acute side effects. The follow-
up should be prolonged to study both local control at long-term and late toxicity.
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Introduction
In adults, uveal melanoma is the most common primary intraocular malignancy. 
Distant metastases will occur in about fifty percent of the cases with a maximum 
death rate at two to three years after the primary diagnosis. Uveal melanoma has 
traditionally been treated by enucleation of the tumor-containing eye. From 1970 on, 
various eye sparing treatment modalities have been developed with as aim an optimal 
sparing of visual function. Nowadays, for small and medium sized uveal melanomas 
radiotherapy has become the first choice of treatment. Brachytherapy appears to be a 
good alternative for enucleation in the treatment of small uveal melanoma, according 
to recent comparative studies 1, 2. For medium sized tumors, proton beam and helium 
ion radiation techniques are widely used 3-9. Radiosurgery for uveal melanomas has 
been introduced in 1987 with excellent results of local control 10-13. However, the most 
important disadvantage of single fraction high dose radiosurgery is an enhanced 
complication probability, which causes the loss of radiobiological sparing if critical 
structures are adjacent to the tumor 10, 13-15. Moreover, the invasive frame as applied 
with radiosurgery is rather uncomfortable for patients and less suitable for fractionated 
treatment schemes. Fractionated stereotactic radiotherapy (by the use of a linear 
accelerator (LINAC)) reduces the effective dose in the surrounding tissues with a delivery 
of an equivalent effective dose to the tumor. The relocatable frame being non-invasive 
is also more convenient for patients. A longitudinal cohort study has been initiated 
in our clinic in order to study both the effectiveness and the safety of this treatment 
modality. Patients with uveal melanoma are being treated by fractionated LINAC-based 
stereotactic radiation therapy (fSRT), following a standard treatment protocol.
Methods and Materials
Study design 
This report evaluates the safety and efficacy of fSRT for uveal melanomas by describing 
the results of the first 38 patients treated in a prospective, consecutive series, one-
center clinical study. This trial will continue and patients will be followed for 10 years 
to study late side effects and melanoma-related death. For this study approval was 
obtained from the Institutional Review Board at this institution. All patients are 
informed about the different treatment modalities and signed an informed consent.
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All consecutive patients with uveal melanoma of choroid or ciliary body smaller than 
12 mm of thickness and 16 mm of diameter were included. Patients were treated if all 
criteria for head and eye fixation were within fixed limits. Patients should be at least 18 
years with a WHO performance status of 0-1. They were excluded if there was clinical 
evidence for metastatic disease.
Patients
Between 1999 and 2003, 38 uveal melanoma patients (21 male, 17 female) with a 
mean age of 61 years were included into the study (Table 1). At diagnosis, thirty-six 
patients had visual symptoms, including a declined vision in 27 patients, light flashes, 
metamorphopsia (change in shape of an object) and floaters (“floating flies”) in 11 
patients, cataract in two and vitreous hemorrhage in another two patients.
table 1  General Data and Tumor Characteristics
characteristics Mean Sd na
Age (years) 61
Gender
Male 21
Female 17
Size (mm)
Diameter
Horizontal 11.1 2.3
Vertical 10.0 2.3
Prominence 6.4 2.6
Shape
Dome 26
Mushroom 12
Location
Anterior 1 20
Posterior 17
Ciliary body 1
Distance to critical structures (mm)
Fovea 3.6 3.1
Papil 4.1 3.0
Visual Acuity 2 0.21 0.17
a Total number of patients is 38
1 Ora serrata and equator
2 Visual acuity before treatment of affected eye
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Pre-irradiation assessment
All patients were examined at the ocular-oncology clinic (G. Luyten), which included 
a full ophthalmologic examination and A and/ or B-scan ultrasonography. In specific 
cases fluorescence angiography was performed to confirm the diagnosis and / or to 
establish tumor progression. All patients had a complete physical examination before 
SRT, a chest X-ray, liver function tests and liver ultrasonography.
Tumor data
The prominence of the tumors varied between 2.2-11 mm, with a mean size of 6.4 mm; 
the mean diameter was 10 mm in horizontal and 11 mm in vertical direction (Table 1). 
The mean distance of the tumor to critical structures was 3.6 mm and 4.1 mm for the 
fovea and optic nerve respectively. About half of the tumors was located anteriorly, 
including one ciliary body melanoma, the other half at the posterior pole (Table 1 and 
2).
table 2  Tumor Location (number of patients)
Nasal Central Temporal
Cranial 5 8 7
Central 0 3 5
Caudal 3 3 4
The uveal melanoma stereotactic frame
For the purpose of stereotactic irradiation of uveal melanoma, an extra construction, 
with a blinking light in front of the unaffected eye and a camera positioned in front 
of the diseased eye, was attached to a non-invasive relocatable Gill Thomas Cosman 
stereotactic frame (GTC frame™, Radionics, Burlington, USA) 16, 17. The position of the 
blinking light can be adjusted to achieve an optimal position of the affected eye for 
irradiation. More detailed information about the Rotterdam eye fixation system is 
published previously 18.
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Planning and treatment
Preceding treatment planning, a MRI scan (1.5 Tesla; axial and sagital T1w SE 1 and 3 mm-
slices, and occasionally axial T2w TSE 3mm- slices) was made of the orbit of the affected 
eye. A planning CT scan with contrast (Omnipaque®) was performed (AcQSim, Philips™) 
with the localizer frame positioned on the GTC frame and with the affected eye in 
treatment position recorded by the camera (1.5-mm slices with an index of 1 mm). The 
intended position of the eye was recorded by a snapshot on which the circumferences 
of the eye, iris and pupil were drawn; these circumferences were used for verification 
of the intended position of the eye during treatment. Both scans were matched in 
order to improve the accuracy of delineation of the gross tumor volume (GTV), using 
ImageFusion™ Version 2.02 (Radionics). The GTV enclosed the primary lesion contoured 
on CT, corrected for any extension of the visible lesion as observed on MRI and taking 
into account the findings of ultrasound imaging and fundus photography. Also, the 
critical structures were delineated on CT, i.e. the lens with ciliary body of the affected 
eye, the contralateral eye and the optic nerves. The planning target volume (PTV) was 
constructed by adding a 3 dimensional margin of 2 mm to the GTV. A treatment plan 
was made using stereotactic arcs of 6 MV photons (XKnife RT™ 1.03, Radionics), with 
one or more isocenters (Figure 1). A total dose of 50 Gy in 5 fractions was prescribed 
to the 80 % isodose surface, encompassing the PTV. Doses of 4 Gy per fraction in the 
optic nerve and 2.5 Gy per fraction to maximal one-fourth of the volume of the lens and 
ciliary body were considered to be acceptable accepted doses.
All patients received 50 Gy in 5 consecutive days, i.e. from Monday to Friday. Before 
each treatment the position of the skull within the GTC frame was checked by depth 
confirmation helmet (DCH) measurements, as described in a former article 18. The 
affected eye was immobilized during the stereotactic irradiation in the intended 
treatment position by means of the eye fixation device as described above and was 
monitored by the camera during irradiation (Figure 2).
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Follow-up
After irradiation, patients were examined according to the protocol after six weeks, 
followed by a three monthly evaluation during the first two years; after two years the 
examinations were every four months. The follow-up program included ophthalmoscopy 
of the tumor-containing eye and the contralateral eye, measurement of the intraocular 
pressure, split lamp examination and B-scan ultrasonography of the affected eye.
The mean follow-up was 25 months, with a range of 10 to 36 months. No patients were 
lost to follow-up.
FigUre 1  Example of treatment planning; 3D view of right eye from anterior position The inset 
is the eye without beams: The tumor is indicated by an arrow; other structures are the lens and 
ciliary body, optic nerve, lacrimal gland and eyeball. For this planning, 5 arcs were used.
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FigUre 2  Treatment of patient
Patient gazes at the blinking light and a camera monitors the diseased eye.
Analysis
Endpoints
The primary endpoints are the acute toxicity after 3 months and local control after 3 
months, 1 and 2 years, respectively. The secondary endpoints are the survival after 5 
and 10 years.
Definition of local control and response
Local control is defined as lack of progressive disease. Complete response is a completely 
flat scar. A decrease of tumor thickness of more than 50% is partial response, while 
progressive disease is a tumor growth of more than 25%; the remaining responses are 
defined as stable disease.
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Visual acuity
Since it was expected that the course of best corrected visual acuity (BCVA) depended 
on the location of the tumor, patients were divided into posterior and anterior located 
tumors.
Retinal detachment
The amount of exudative retinal detachment was classified into 5 groups according to 
the EORTC scale (0 no detachment to 4 complete detachment) (Figure 3).
FigUre 3  Retinal detachment as a function of time of follow-up 
Four classes of detachment: 0= no subretinal fluid, 1= subtle fluid, 2= local fluid, 3 = detachment 
of half of the retina, 4= total ablatio. On the y axis the percentage of the total number of treated 
patients is presented.
Statistics
Since the distribution of the values was ordinal, the Wilcoxon Signed Rank Test was 
used to analyze the difference between the BCVA before and 12 and 24 months after 
therapy for all tumors as well as for anterior and posterior located tumors, separately.
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Results
Dose in critical structures
Twenty-five percent of the volume of the ciliar body received a mean of 277 cGy per 
fraction, with a median of 167 cGy, while 11 patients received more than 250 cGy in at 
least 25% of the ciliar body.
The mean of the maximum doses in the optical nerve per fraction was 457 cGy (median: 
351 cGy); 15 patients received more than the allowed 400 cGy per fraction in the optical 
nerve.
Tumor control
The local control up to now is 100% after a mean follow-up of 2 years, although it takes 
up to six months until a decrease in tumor thickness can be detected (Table 3). One 
year after fSRT 13 percent had partial response, while 87 percent had a stable disease, 
according to our definition. After 2 years the mean prominence was halved (Figure 4) 
and the percentage of patients having a partial response was increased to 36. 
Three patients developed metastases, all located in the liver. In retrospect, 1 patient 
had a suspicious lesion in the liver at diagnosis. Two patients developed metastases 1 
and 2 years after diagnosis, respectively.
After a mean follow-up of 25 months the overall survival was 67%. Five patients died, 
of which 3 patients due to a melanoma related cause at 13, 26 and 30 months after 
therapy, respectively. One patient died due to metastasized ovarian cancer. The fifth 
patient died from peritonitis caused by a perforated gastric ulcer.
table 3  Tumor Regression (MM)
time of Follow-up
(number of patients)
diameter1 Prominence
Before After Effect Before After Effect
3 months (38) 10.6 10.5 1% 6.4 6.2 3%
6 months (36) 10.4 10.0 4% 6.3 5.3 16%
12 months (32) 10.5 9.8 7% 6.2 4.6 26%
18 months (22) 10.4 9.4 10% 5.7 3.2 44%
24 months (15) 10.6 9.2 13% 5.3 2.7 47%
1 Diameter: Mean of horizontal and vertical dimensions
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FigUre 4  Example of decrease of prominence
Female patient of 59 years, uveal melanoma in left eye; the prominence of 6.6-mm before 
treatment decreased to 0.6-mm 12 months after treatment; subretinal fluid vanished. Both 
ultrasonography scans were performed using 20 MHz (gain of 80, depth of 4-mm).
Toxicity
Visual acuity
The BCVA gradually declined from 0.21 at diagnosis to a mean acuity of 0.06 two years 
after therapy (Figure 5). A significant decline in VA was found in the posterior located 
tumors. For the anterior located tumors, no significant difference between the BCVA 
before and 2 years after therapy could be found. However, an initial decline of 42 
percent at 3 months after therapy was seen.
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FigUre 5  Best corrected visual acuity before and after therapy
Best corrected visual acuity at diagnosis and after therapy for all tumors and for tumors located 
in the posterior (dashed line) or anterior (dotted line) part of the eye.
Retinal detachment
The retinal detachment before therapy was completely resolved two years after 
therapy (Figure 3). Three patients with a tumor in the posterior pole and subretinal 
leakage were treated with transpupillar thermotherapy to resolve the subretinal fluid; 
two patients were treated at 12 months and 1 patient at 22 months after therapy.
Side effects
The side effects are divided into subgroups as depicted in Table 4. The columns 
represent the symptoms after 3, 6, 9, 12 and 24 months of follow-up, respectively. 
During follow-up most patients did not experience any significant side effects.
Acute side effects
The most common symptoms after 3 months of follow-up were mild conjunctival 
symptoms, such as hyperemia, irritation, tears and chemosis, visual symptoms (light 
flashes, mononuclear diplopia, floaters and metamorphopsia), loss of hair or lashes 
and fatigue. One patient suffered from vitreous hemorrhage at diagnosis already. One 
patient underwent an enucleation 2 months after irradiation, because of total retinal 
detachment and suspicion of tumor growth. The pathologist however found massive 
inflammation; no vital tumor cells could be detected.
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table 4  Clinical Symptoms
Symptoms
Months after therapy (number of patients)
3 (38) 6 (36) 12 (32) 18 (22) 24 (15)
No complaints 19 22 23 14 7
Conjunctival symptoms 10 3 1 1 0
Loss of lashes or hair 6 1 1 0 0
Visual symptoms 5 1 1 1 1
Fatigue 5 0 0 1 0
Pain 4 2 1 1 1
Dry eye 1 3 3 3 3
Cataract 1 0 1 0 0
Retinopathy 0 0 1 2 1
Optical neuropathy 0 0 2 2 1
Other1 1 3 4 2 1
1 Branch retinal vein occlusion (1), subretinal bleeding (1), vitreous hemorrhage (2) and neovascular 
glaucoma (1)
Late side effects
One and 2 years after fSRT 64% and 47% of the patients remained free of serious late 
toxicity. The most serious adverse effects after 1 year of treatment were neovascular 
glaucoma (5%), retinopathy (5%), optical neuropathy (9%), dry eye (9%) and subretinal 
bleeding (5%). So far, no enucleations due to late side effects were required.
Discussion
Several eye sparing treatment options have been developed during the last couple of 
decades. The most suitable modality depends on both the size and the location of the 
tumor. Stereotactic radiation therapy has proven to be a good alternative for medium 
and large sized tumors 11-15, 19, 20. Since a few years fSRT has been used with as important 
advantage the better sparing of normal tissues radiobiologically, by fractionating the 
dose and physically, by a 3-dimensional approach 21, 22.
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Uveal melanomas are known to be relatively resistant to radiation 23, 24. Van den 
Aardweg et al., analyzing the effects of split-dose irradiation on uveal melanoma cell 
lines, concluded that the radiosensitivity is dominated by the intrinsic factors, i.e. the 
α-component 25. A total dose of 50 Gy, in 5 daily fractions of 10 Gy, should be sufficient to 
kill even the most radio-resistant tumor cells and yet, spare critical structures. However, 
a great variation in radiosensitivity between different cell lines was found indicating 
that this schedule is probably overkill for more sensitive cell lines. More research is 
necessary to determine specific morphologic and histological tumor markers in order 
to individualize dose fractionation schedules.
In this study, local control up to 2 years after therapy is excellent without progressive 
disease so far. These data are comparable to published results of other treatment 
modalities, such as brachytherapy 7, 20, 26-28, proton therapy 3, 4, 6-9, 29 and radiosurgery 
11-15, 19, 20. Although preliminary, these results demonstrate that fSRT is an effective 
treatment modality for medium and large sized uveal melanomas. Whether the extent 
of decrease in prominence of uveal melanoma is related to stable disease, partial or 
complete response is questionable. 
The observed delayed tumor regression is also described by other authors 21, 30. The 
reason for this delay can (partly) be explained by the development of edema as 
a reaction on radiation therapy as described in several articles about stereotactic 
radiation therapy for other tumor sites 31, 32.
Three out of 32 patients developed liver metastases 1 year after treatment. A longer 
follow-up however is needed to analyze the rate of metastases, since these tumors are 
known to metastasize rather late 33-35.
The BCVA two years after fSRT is disappointing. Several explanations for this result can 
be found. At first, half of the tumors were located in the posterior pole. From our analysis 
the BCVA of eyes with posterior located tumors was significantly worse when compared 
to the eyes with anterior located tumors, which had still a useful BCVA after therapy. 
Besides, most of the patients had declined vision at diagnosis already. Furthermore, 
the tumor size was considerable, with a mean diameter before therapy of 10.5 mm. 
Also, the mean distance of the tumor to the fovea was 3.6 mm. These properties are 
described as being risk factors for impaired VA in former publications of radiation 
therapy for uveal melanoma 3-5, 9, 28, 36. A comparison with brachytherapy is difficult to 
make as the mean tumor size in this treatment group is often smaller (in particular 
the prominence) and the overall pre-treatment BCVA is better 7. Nevertheless, given 
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the results, brachytherapy seems to be the preferred treatment for smaller posterior 
located melanoma. However, fSRT remains a useful treatment options for posterior 
located tumors too large for brachytherapy and for juxta papillary tumors. Even if there 
is no vision left, the bulbus as well as perception of light can still be preserved. The 
initial decline of BCVA in anterior located tumors of 25% after 3 months can probably 
be explained by vitreous hemorrhage that resolves during further follow-up.
The acute side effects were mild and mostly reversible. One eye was enucleated 2 
months post fSRT on suspicion of tumor growth. The pathology however, described 
massive inflammation. No vital tumor cells were found. Consequently, this case is 
more likely to be a serious complication than tumor growth; reconstruction of the 
case showed a very high tumor dose. The late side effects so far turned out to be mild, 
although more serious effects such as retinopathy and optical neuropathy occurred 
after 1 year of follow-up, both in 2 patients. The conjunctival and visual symptoms 
seemed to resolve during further follow-up. However, a dry eye was more common. 
The other side effects enclosed a subretinal hemorrhage in 1 patient 1 year after 
treatment, a branch retinal vein occlusion in 1 patient after 2 years of follow-up and 1 
vitreous hemorrhage 6 months after therapy. Neovascular glaucoma is often described 
in literature as a common late side effect 3-5, 7, 12, 14, 15, 19, 21, 37. So far, neovascular glaucoma 
occurred just in 1 patient; the reason for this is perhaps the rather strict maximum 
dose criteria accepted for the anterior segment of the eye. Although preliminary, the 
incidence and degree of the side effects are promising as compared to the literature 
3-7, 9, 10, 12, 14, 15, 19-21, 37, 38 . Alas the follow-up is too short and the number of patients is too 
small to draw firm conclusions.
Conclusion
In summary, fractionated stereotactic radiation therapy of uveal melanoma results in 
excellent local control with only mild side effects. Therefore, it seems to be an effective 
and safe treatment modality for uveal melanoma. However, the BCVA two years after 
therapy is declined, mainly because of the considerable tumor size and the location of 
tumor; half of the tumors were located in the posterior part of the eye. Finally, longer 
follow-up with a larger number of patients is needed for long-term local control, late 
toxicity and survival.
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Abstract
Purpose
To determine local control, late toxicity and metastatic free survival (MFS) of patients 
treated with fractionated Stereotactic Radiation Therapy (fSRT) for uveal melanoma 
(UM).
Methods and Materials
Between 1999 and 2007, 102 UM patients were included in a prospective study of a 
single institution (median follow-up (FU) 32 months; median tumor thickness 6 mm); 
5 fractions of 10 Gy were given. Primary endpoints were local tumor control and late 
toxicity (including visual outcome and eye preservation). Secondary endpoint was MFS.
Results
Local tumor control was achieved in 96% of the patients. Fifteen enucleations were 
performed, 2 to 85 months after radiation. Four eyes were enucleated because of local 
tumor progression. Nine patients developed grade 3 or 4 neovascular glaucoma (NVG), 
19 developed severe retinopathy, 13 developed opticoneuropathy grade 3 or 4, 10 
developed cataract grade 3 and 10 patients suffered from keratitis sicca. Best corrected 
visual acuity (BCVA) decreased from a mean of 0.26 at diagnosis to 0.16, 3 months after 
radiation and it gradually declined to 0.03, 4 years after therapy. The 5-year actuarial 
MFS was 75% (95% CIs: 62–84%).
Conclusions
fSRT is an effective treatment modality for uveal melanoma with a good local control. 
With that, fSRT is a serious eye sparing treatment modality. However, our FU is relatively 
short. Also, the number of secondary enucleations is substantial, mainly caused by NVG.
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Introduction
Uveal melanoma (UM) is the most common primary eye cancer in adults [1]. Still, UM 
occurs infrequently, having an annual age adjusted incidence of 4 to 7 per million [1]. 
Generally, uveal melanomas arise from the choroid (72%); however, they may also 
appear in the ciliary body (23%) or iris (5%). Currently next to enucleation, patients can 
be offered several eye sparing treatment options. The preferred treatment is influenced 
by a number of patient and tumor related factors, such as general condition, age, size 
and location of the tumor, visual acuity of the contralateral eye and the presence of 
metastases at diagnosis. Beside radiotherapy, transscleral resection, transretinal 
resection and phototherapy are used for the primary treatment of uveal melanomas. It 
is beyond the scope of this paper however, to discuss these modalities.
Regarding radiotherapy, brachytherapy appears to be an effective treatment modality 
for UM [2-9]. For medium and large sized tumors, heavy particle radiation techniques 
(proton and helium ion beam) as well as stereotactic radiation therapy (SRT) are other 
eye sparing treatment options[10-14]. Single fraction SRT (“radiosurgery”) for UM, has 
been introduced in 1987, with local control rates between 90 and 98 percent [15, 16]. 
The most important shortcoming of radiosurgery is the loss of radiobiological sparing 
of adjacent critical structures. Fractionated stereotactic radiotherapy (fSRT) reduces 
the effective dose in the surrounding tissues with a delivery of an equivalent effective 
dose to the tumor. 1999, a longitudinal cohort study has been initiated in our institute, 
in which patients with UM were treated with fSRT. Preliminary results demonstrated 
that fSRT is well tolerated and can be safely implemented in the treatment of UM with 
excellent short term local control and mild acute side effects [17, 18]. However, to 
determine the efficacy of fSRT, not only local control and survival at long-term, but also 
late toxicity is an issue to be studied in great detail. In this paper, the primary endpoints 
local tumor control and late toxicity, including visual outcome and eye preservation, as 
well as the secondary endpoint, metastastic free survival (MFS) of 102 UM patients are 
analyzed.
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Methods and Materials
Study design
In 1999 a prospective single center clinical trial was initiated in order to study both 
the safety and efficacy of fSRT for UM. In this report the local control, late toxicity 
and survival up to 5 years follow-up (FU) were evaluated. Approval for this study 
was obtained from the Institutional Review Board at the Erasmus Medical Center. All 
patients signed an informed consent.
Patients of at least 18 years of age with a WHO performance status of 0 or 1 and with 
UM of choroid or ciliary body with a tumor thickness smaller than 12 mm, a diameter 
of smaller than 16 mm and no clinical evidence for metastatic disease were included. 
Between 1999 and 2007, 102 consecutive UM patients (58 male, 44 female) were 
included into the study. Both characteristics of patients and tumor data are presented 
in table 1. 
Treatment planning
Patients were immobilized by means of a non-invasive relocatable Gill Thomas Cosman 
stereotactic frame (GTC frame™, Radionics, Burlington, USA) [19, 20], modified with the 
Rotterdam eye fixation system. A treatment plan was made using stereotactic arcs of 6 
MV photons (XKnife RT™ 1.03, Radionics). A total dose of 50 Gy (5 fractions of 10 Gy) was 
delivered on 5 consecutive days. The Rotterdam eye fixation system and the treatment 
techniques per se, have been detailed in previous publications [17, 18]. 
Follow-up (FU)
Six weeks after irradiation, patients were examined, followed by a three monthly 
evaluation (including lab tests) during the first two years; after two years the 
examinations were every four months. The median FU was 32 months (2 to 92); one 
patient was lost to FU 48 months after initiation of therapy. 
Analysis
Endpoints
Primary endpoints were local tumor control and late toxicity after 1 to 5 years, including 
visual outcome and eye preservation. The actuarial metastatic free survival (MFS), with 
95% confidence intervals (CI), after 5 years was determined as the secondary endpoint.
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table 1  General Data and Tumor Characteristics
characteristics Median (range) na
Age (years) 63 (28-83)
Gender
Male 58
Female 44
Follow-up (months) 32 (2-94)
Size (mm)
Diameter 11.9 (7.5-18.9)
Tumor thickness 6.0 (2.2-11.1)
TNM*
T1a 18
T2a 45
T2b 2
T3a 33
T3b 2
T4a 1
T4b 1
Shape
Dome 82
Mushroom 18
Diffuse 2
Laterality
Right 38
Left 64
Location**
Anterior 1 55
Posterior 2 41
Ciliary body 6
a Total number of patients is 102
* TNM staging of malignant melanoma of the uvea, 7th edition of AJCC
** Location of epicenter of the tumor
1 Ora serrata and equator
2 Post equator
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Toxicity Scoring Criteria
The common terminology criteria for adverse events (CTCAE, version 3.0) was used, 
to evaluate toxicity [21-23], table 2. Retinal detachment was classified into 5 groups 
according to the EORTC scale (0 no detachment to 4 complete detachment). Visual 
acuity was determined: The best corrected visual acuity (BCVA) was converted into 
linear values in order to calculate the mean values of the group.
table 2  Toxicity
ctc
grade a
1 2 3 4 time at diagnosis b
(months)
cataract 8 5 10 - 12 (3-42)
dry eye 8 8 2 - 6 (3-24)
glaucoma * 2 2 3 6 30 (12-60)
keratitis 3 4 3 0 6 (3-12)
Optic disc edema 0 2 9 4 18 (12-24)
retinopathy 10 11 13 6 24 (12-72)
uveïtis 0 1 1 0 6
vitreous haemorrhage 2 4 4 - 15 (3-48)
a Total number of patients
b Median (range)
* All caused by neovascular glaucoma
Dose calculation
For all patients minimum (D5) , median (D50) and maximum (D95) doses of both PTV and 
critical structures were calculated. The dose given in at least 25 percent of the ciliary 
body (lens included) (D25) was also computed, since this was a planning constraint.
Statistics
Logistic regression analyses were performed to analyze the relationship between the 
risk on toxicity versus possible risk factors (such as dose and tumor size and location). 
Tests with a p value of less than 0.05 were considered to be significant.
MFS was calculated using the actuarial method. We calculated time to first detection 
of metastases.
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Results
Local tumor control
In general, tumor thickness started to decrease 6 months after initiation of radiation 
therapy. Of the 102 tumors, 6 remained stable in thickness and underwent within a 
time frame of 10 to 27 months transpupillar thermotherapy. These tumors were located 
equatorial (2) or post-equatorial (4); none of the ciliary body tumors failed. There was 
no correlation with diameter or tumor thickness and local failure (p=0.3). Eventually, 
out of these 6 patients, 4 had to be enucleated after a median FU of 40 months (14-85 
months) due to tumor progression.
Toxicity
Ten patients developed cataract grade 3; all of these underwent a lens extraction, 
followed by an implantation of an intraocular lens. Patients that received a higher dose 
into the lens and ciliary body appeared to have a higher probability of developing a 
cataract grade 3. The logistic regression analysis outcome for developing a cataract 
grade 3 by radiation therapy with minimum, median and maximum doses appears to 
be significant (that is p=0.01, p= 0.003 and p=0.003, respectively). A median dose of 
5 Gy/fraction in the lens and ciliary body caused a cataract in 50 percent of the cases 
(TD50, see also figure 1a).
In 19 patients grade 3 and/or 4 retinopathy occurred. No significant influence was 
found of tumor thickness, diameter, maximum dose and the distance to the fovea. 
Thirteen patients developed grade 3 or 4 opticoneuropathy. The received median dose 
(p=0.02) and maximum dose (p<0.001) in the optical nerve and the distance between 
the PTV and the optical nerve (p=0.01) were statistically significant predicting factors 
for opticoneuropathy (figure 1b). A maximum accepted dose of 4 Gy/fraction in the 
optical nerve corresponded with a 10% probability of severe opticoneuropathy; the 
TD50 was 9.6 Gy/fraction.
Before treatment, retinal detachment (RD) was present in 57 patients, varying from 
grade 1 to grade 3. In 11 cases, RD aggravated directly after radiation therapy. Eight 
patients were treated for RD with Triamcinolone, 4 of which underwent a vitrectomy 
in the course of FU. Two out of 5 patients, who developed RD grade 4, had to be 
enucleated (1 because of secondary endophthalmitis after vitrectomy). Eventually, 
RD resolved in the rest of patients within 2 years. Larger melanomas (in thickness and 
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diameter) showed to have a higher probability of a grade 3 and 4 RD (p<0.001 and 
p=0.001, respectively). A tumor thickness of 9.6 mm corresponds with a 50% probability 
on grade 3 or 4 RD. Also, grade 2 or 3 RD before treatment appeared to be a prognostic 
predicting factor for the development of grade 3 and 4 RD (p<0.001).
Nine patients developed grade 3 and 4 neovascular glaucoma (NVG), and 8 of them had 
to be enucleated. Tumor thickness (p=0.02) and the appearance of grade 3 retinopathy 
(p=0.003) were predicting factors. The minimum, median and maximum doses received 
in the ciliary body were not significantly different compared to patients without 
glaucoma. 
Ten patients developed dry eye syndrome (DES) grade 2 and 3. One patients had 
temporarily acute symptoms of DES. A clear relationship between the appearance of 
DES and dose to the lacrimal gland was found; this is reported in detail (Muller et al 
2009) [18].
Visual acuity
Directly after radiation, the best corrected visual acuity (BCVA) decreased from a mean 
of 0.26 at diagnosis to 0.16 after 3 months of FU, after which it gradually declined to 0.03, 
4 years after therapy. Particularly in posteriorly located tumors, the BCVA decreased to 
< 0.1. Anterior located tumors showed a stable BCVA with a mean of 0.16 after 4 years. 
Tumor location was correlated with both preoperative vision (p=0.048) and BCVA after 
18 months of FU (p=0.02; even when corrected for preoperative vision). Also, a higher 
maximum dose to the optical nerve corresponded to a lower visual outcome (p< 0.05). 
Neither tumor thickness nor diameter correlated with BCVA. A low pre-irradiation BCVA 
score did show a statistically significant correlation with low visual outcomes after 
treatment.
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FigUre 1  Graphs of logistic regression analysis; toxicity versus dose
The y-axis represents the appearance of cataract grade 3 (figure 1a) or optic neuropathy grade 
3 or 4(figure 1b): 0 is no toxicity grade 3 or 4, 1 is toxicity grade 3 or 4; on the x-axis the dose 
delivered in the lens and ciliary body (figure 1a) or optical nerve (figure 1b) is pointed out; each 
cross and circle represents a single patient; the drawn line depicts the chance on toxicity versus 
the dose.
a. Cataract versus median dose in lens and ciliary body (cGy/fraction) 
b. Optic neuropathy (ONP) versus maximum dose in optic nerve (cGy/fraction) 
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Eye preservation
Because of various causes as listed in table 3, 15 patients were enucleated 2 to 85 months 
after radiation. One patient developed secondary endophthalmitis after vitrectomy. At 
the onset of the study, one patient was enucleated 2 months after fSRT on suspicion 
of tumor growth. The pathology however, described massive inflammation. Tumor 
thickness was not a significant prognostic factor for enucleation (p=0.15).
Metastatic free survival (MFS)
The 5-year actuarial MFS was 75% (95%CI: 62-84%). Fourteen patients developed 
distant metastases. In all cases the liver was affected, but also metastatic deposits 
were found in the lung (1 case), the peritoneum (1 case), a lymph node near the 
hepatojejunal ligament (1 case) and the skin (1 case). In the univariate analysis, no 
significant prognostic factors could be established for distant metastases, although a 
trend was seen for diameter (p=0.080) and tumor thickness (p=0.15).
table 3  Causes of Enucleation
description Frequency a time of Follow-up b (months)
Progression 4 40 (14-85) b
Toxicity 9
Neovascular glaucoma 8 33 (16-55)b
Retinal detachment 1 14
Endophthalmitis after vitrectomy 1 9
Massive inflammation mistaken as progression 1 2
a Total number of patients 
b Median (range)
Discussion
New eye sparing treatment modalities for UM have emerged and reported in the last 
decades [4, 15, 18, 24-28]. One of these new modalities is the use of fSRT. This paper 
reports on the results of fractionated SRT of a single institution with patients treated 
between 1999 and 2007. In our study we tried to describe not only the local tumor 
control and late toxicity, but also relate it to radiation dose and tumor characteristics. 
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Local tumor control
We found an overall local tumor control rate of 96%. Because of stable disease, 
transpupillar thermotherapy (TTT) was applied in 6 patients; eventually, 4 failures 
after fSRT and TTT had to be enucleated. The median time to progression was 3 years. 
Dieckman et al reported on a series of 90 patients, treated with a similar radiation 
scheme; a local control rate of 98 percent was observed [29]. Other reports on the use 
of SRT reported control rates of 91 to 97 percent [15, 16, 18, 28, 31, 32]. These data are 
also in agreement with other radiation modalities in literature [10, 12, 16, 29, 32-34]. 
The role of TTT in UM however, is debatable [4].
Toxicity
The BCVA was disappointing, especially in posteriorly located tumors. Visual outcome 
is variably reported in the literature [9, 35-37]. The visual acuity before treatment was 
clearly correlated with the visual outcome after treatment, which is in agreement with 
literature [15, 16, 37]. Also, the occurrence of retinopathy and or opticoneuropathy 
have negative impact on the visual outcome. In our population, 18% developed grade 
3 or 4 retinopathy. In literature, retinopathy was reported in 10 to 81% of the cases [5, 
29, 32, 33]. It is well known that the occurrence of (severe) radiation retinopathy is dose 
dependent: both high total doses (>25 Gy) as well as a high dose per fraction (>2 Gy) 
are well accepted known risk factors [38, 39]. However, in contrast to the literature, in 
this study no other significant factors were found for retinopathy [39].
Thirteen patients (13%) developed opticoneuropathy grade 3 or 4, which is in 
accordance with the reported 20% after fSRT in literature [29]. Other treatment 
modalities show opticoneuropathy rates of 8 – 46 % (BT) and 8 – 23% (proton therapy) 
[5, 33, 41, 43,44]. Predicting factors for optic neuropathy were tumor location and dose 
received in the optic nerve. The maximum dose we accepted in the optical nerve, i.e. 
4Gy/fraction, corresponded with a 10% chance on developing opticoneuropathy.
Similar to the data published for brachytherapy [40, 41] and for periocular located 
tumors [42], the occurrence of grade 3 cataract in (10% of ) our patients was clearly 
dose dependent.
Neovascular glaucoma (NVG) appeared to be the most serious complication of fSRT. 
Although grade 3 or 4 NVG occurred only in 9 patients yet (table 2), out of these 9, eight 
had to be enucleated. This number of NVG compares favorably with published NVG 
rates of 9 – 60% [29, 32, 33, 36, 41, 44]. However, our FU is relatively short. Contrary to 
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what we expected, the tumors of these 9 patients were not located anteriorly, nor did 
they receive a substantial higher dose to the ciliary body [43]. Tumor thickness and the 
occurrence of radiation retinopathy grade 3 turned out to be predicting factors for NVG, 
which is also reported in literature [41, 44]. Our hypothesis is that the physical reaction 
on ischemic retinopathy, such as vascular proliferation, might also affect the vessels in 
the ciliary body, with NVG as a result. Hopefully, in near future, better understanding 
and treatment of NVG with new techniques, such as iridocyclectomy, will decrease the 
number of secondary enucleations [41].
The use of univariate analyses may not be accurate in view of the multifactorial etiology 
of most toxicities. However, due to the small numbers of our study it was not possible 
to run multivariate analyses.
Metastatic free survival(MFS)
In this study the 5-year actuarial MFS was 75%. This is comparable with the survival 
outcome of proton beam therapy for similar sized tumors [10, 36]. According to literature, 
in case of a local recurrence, the metastases rate increases [14, 45-49]. However, in this 
study only 4 patients developed local recurrence and 1 of these developed metastases. 
These numbers are in fact too small to draw any meaningful conclusions. Given the 
literature, tumor size appears to be an important predictor for both overall- and 
metastatic free survival [50]. Although there was a trend for larger tumors to develop 
more metastases, this was not significant. However, numbers of patients are small and 
FU time might not be sufficient, since uveal melanomas metastasize relatively late. In 
concordance with the literature, our patients survived after developing metastases a 
median of 9 months [4, 51-57].
Limitations and challenges:
In our study, the number of patients is relatively small and median FU might be too 
short. Keeping this in mind we are apprehensive in drawing conclusions out of the 
results of our series. From the onset of our study we realized that a long FU would 
be preferable in UM patients. Therefore, the FU of our patient cohort is still ongoing 
and we will re-evaluate our results after a longer period of FU. Also, due to the rare 
incidence of uveal melanomas, it was not possible to start a randomized study in which 
fSRT could be compared with other treatment modalities, such as brachytherapy, 
proton therapy and enucleation. It is of interest however, not only to compare our data 
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set to literature, but to compare our data with equal tumor and patient characteristics 
treated with other eye sparing modalities and enucleation. Currently, our data are 
being compared with the patients treated with brachytherapy at the LUMC (Leiden) 
and will be published soon. Another difficulty in inter-study comparison of results is 
the existence of different toxicity grading systems. Unfortunately, since they all have 
their specific (dis-)advantages, there is no clear cut solution for this problem. Finally, 
from the onset of our study, quality of life questionnaires were given to all UM patients 
before treatment (fSRT or enucleation) and during FU. In near future, we will evaluate 
the quality of life of patients treated with fSRT versus enucleation; this will be combined 
with cost-benefit analyses.
Conclusion
In conclusion, fSRT turned out to be an effective treatment modality for uveal 
melanoma, with a good local control. With that, fSRT is a serious eye sparing treatment 
modality comparable to other external beam techniques. However, our follow-up up 
to this point is short and the number of patients relatively small. Also, the number 
of secondary enucleations is substantial, mainly caused by NVG. Furthermore, the 
morbidity is influenced by tumor size and location. Treatment preference should be 
based on tumor characteristics and patient’s preferences.
Chapter 462
References
1  Singh, AD, Topham, A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 
2003;110:956-961.
2  Bell, DJ, Wilson, MW. Choroidal melanoma: natural history and management options. Cancer Control 
2004;11:296-303.
3  Damato, B. Developments in the management of uveal melanoma. Clin Experiment Ophthalmol 
2004;32:639-647.
4  Damato, B. Treatment of primary intraocular melanoma. Expert Rev Anticancer Ther 2006;6:493-506.
5  Fontanesi, J, Meyer, D, Xu, S, Tai, D. Treatment of choroidal melanoma with I-125 plaque. Int J Radiat 
Oncol Biol Phys 1993;26:619-623.
6  Georgopoulos, M, Zehetmayer, M, Ruhswurm, I, et al. Tumour regression of uveal melanoma after 
ruthenium-106 brachytherapy or stereotactic radiotherapy with gamma knife or linear accelerator. 
Ophthalmologica 2003;217:315-319.
7  Lommatzsch, PK, Werschnik, C, Schuster, E. Long-term follow-up of Ru-106/Rh-106 brachytherapy for 
posterior uveal melanoma. Graefes Arch Clin Exp Ophthalmol 2000;238:129-137.
8  Nag, S, Quivey, JM, Earle, JD, Followill, D, Fontanesi, J, Finger, PT. The American Brachytherapy Society 
recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys 2003;56:544-
555.
9  Packer, S, Stoller, S, Lesser, ML, Mandel, FS, Finger, PT. Long-term results of iodine 125 irradiation of 
uveal melanoma. Ophthalmology 1992;99:767-773; discussion 774.
10  Dendale, R, Lumbroso-Le Rouic, L, Noel, G, et al. Proton beam radiotherapy for uveal melanoma: 
results of Curie Institut-Orsay proton therapy center (ICPO). Int J Radiat Oncol Biol Phys 2006;65:780-
787.
11  Fuss, M, Loredo, LN, Blacharski, PA, Grove, RI, Slater, JD. Proton radiation therapy for medium and 
large choroidal melanoma: preservation of the eye and its functionality. Int J Radiat Oncol Biol Phys 
2001;49:1053-1059.
12  Gragoudas, ES, Lane, AM, Munzenrider, J, Egan, KM, Li, W. Long-term risk of local failure after proton 
therapy for choroidal/ciliary body melanoma. Trans Am Ophthalmol Soc 2002;100:43-48; discussion 
48-49.
13  Gragoudas, ES, Seddon, JM, Egan, K, et al. Long-term results of proton beam irradiated uveal 
melanomas. Ophthalmology 1987;94:349-353.
14  Kodjikian, L, Roy, P, Rouberol, F, et al. Survival after proton-beam irradiation of uveal melanomas. Am J 
Ophthalmol 2004;137:1002-1010.
15  Modorati, G, Miserocchi, E, Galli, L, Picozzi, P, Rama, P. Gamma knife radiosurgery for uveal melanoma: 
12 years of experience. Br J Ophthalmol 2009;93:40-44.
16  Fakiris, AJ, Lo, SS, Henderson, MA, et al. Gamma-knife-based stereotactic radiosurgery for uveal 
melanoma. Stereotact Funct Neurosurg 2007;85:106-112.
17  Muller, K, Nowak, PJ, Luyten, GP, Marijnissen, JP, de Pan, C, Levendag, P. A modified relocatable 
stereotactic frame for irradiation of eye melanoma: design and evaluation of treatment accuracy. Int J 
Radiat Oncol Biol Phys 2004;58:284-291.
18  Muller, K, Nowak, PJ, de Pan, C, et al. Effectiveness of fractionated stereotactic radiotherapy for uveal 
melanoma. Int J Radiat Oncol Biol Phys 2005;63:116-122.
19  Kooy, HM, Dunbar, SF, Tarbell, NJ, et al. Adaptation and verification of the relocatable Gill-Thomas-
Cosman frame in stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 1994;30:685-691.
20  Warrington, AP, Laing, RW, Brada, M. Quality assurance in fractionated stereotactic radiotherapy. 
Radiother Oncol 1994;30:239-246.
21  Cox, JD, Stetz, J, Pajak, TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the 
European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 
1995;31:1341-1346.
Fractionated stereotactic radiotherapy for uveal melanoma, late clinical results 63
22  RTOG/EORTC Late Radiation Morbidity Scoring Schema.
23  Cancer Therapy Evaluation Programm, Common Terminology for Adverse Events, Version 3.0, DCTD, 
NCI, NIH, DHHS March 2003 (http://ctep.cancer.gov). 2003.
24  Zehetmayer, M, Dieckmann, K, Kren, G, et al. Fractionated stereotactic radiotherapy with linear 
accelerator for uveal melanoma--preliminary Vienna results. Strahlenther Onkol 1999;175 Suppl 2:74-
75.
25  Dieckmann, K, Zehetmayer, M, Poetter, R. Fractionated stereotactic radiotherapy for choroidal 
melanoma. Radiother Oncol 1998;49:197.
26  Keunen, JE, Journee-de Korver, JG, Oosterhuis, JA. Transpupillary thermotherapy of choroidal 
melanoma with or without brachytherapy: a dilemma. Br J Ophthalmol 1999;83:1212-1213.
27  Puusaari, I, Damato, B, Kivela, T. Transscleral local resection versus iodine brachytherapy for uveal 
melanomas that are large because of tumour height. Graefes Arch Clin Exp Ophthalmol 2007;245:522-
533.
28  Tokuuye, K, Akine, Y, Sumi, M, Kagami, Y, Ikeda, H, Kaneko, A. Fractionated stereotactic radiotherapy for 
choroidal melanoma. Radiother Oncol 1997;43:87-91.
29  Dieckmann, K, Georg, D, Zehetmayer, M, Bogner, J, Georgopoulos, M, Potter, R. LINAC based stereotactic 
radiotherapy of uveal melanoma: 4 years clinical experience. Radiother Oncol 2003;67:199-206.
31  Mueller, AJ, Schaller, U, Talies, S, Horstmann, GA, Wowra, B, Kampik, A. Stereotactic radiosurgery using 
the Gamma Knife for large uveal melanomas . Ophthalmologe 2003;100:122-128.
32  Krema, H, Somani, S, Sahgal, A, et al. Stereotactic radiotherapy for treatment of juxtapapillary choroidal 
melanoma: 3-year follow-up. Br J Ophthalmol 2009;93:1172-1176.
33  Castro, JR, Char, DH, Petti, PL, et al. 15 years experience with helium ion radiotherapy for uveal 
melanoma. Int J Radiat Oncol Biol Phys 1997;39:989-996.
34  Finger, PT, Berson, A, Ng, T, Szechter, A. Palladium-103 plaque radiotherapy for choroidal melanoma: 
an 11-year study. Int J Radiat Oncol Biol Phys 2002;54:1438-1445.
35  Bergman, L, Nilsson, B, Lundell, G, Lundell, M, Seregard, S. Ruthenium brachytherapy for uveal 
melanoma, 1979-2003: survival and functional outcomes in the Swedish population. Ophthalmology 
2005;112:834-840.
36  Conway, RM, Poothullil, AM, Daftari, IK, Weinberg, V, Chung, JE, O’Brien, JM. Estimates of ocular and 
visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy. 
Arch Ophthalmol 2006;124:838-843.
37  Krohn, J, Monge, OR, Skorpen, TN, Mork, SJ, Dahl, O. Posterior uveal melanoma treated with I-125 
brachytherapy or primary enucleation. Eye 2008;22:1398-1403.
38  Archer, DB, Amoaku, WM, Gardiner, TA. Radiation retinopathy--clinical, histopathological, ultrastructural 
and experimental correlations. Eye 1991;5 ( Pt 2):239-251.
39  Gunduz, K, Shields, CL, Shields, JA, Cater, J, Freire, JE, Brady, LW. Radiation retinopathy following plaque 
radiotherapy for posterior uveal melanoma. Arch Ophthalmol 1999;117:609-614.
40  Puusaari, I, Heikkonen, J, Kivela, T. Effect of radiation dose on ocular complications after iodine 
brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques. Invest 
Ophthalmol Vis Sci 2004;45:3425-3434.
41  Puusaari, I, Heikkonen, J, Kivela, T. Ocular complications after iodine brachytherapy for large uveal 
melanomas. Ophthalmology 2004;111:1768-1777.
42  Takeda, A, Shigematsu, N, Suzuki, S, et al. Late retinal complications of radiation therapy for nasal and 
paranasal malignancies: relationship between irradiated-dose area and severity. Int J Radiat Oncol Biol 
Phys 1999;44:599-605.
43  Kim, MK, Char, DH, Castro, JL, Saunders, WM, Chen, GT, Stone, RD. Neovascular glaucoma after helium 
ion irradiation for uveal melanoma. Ophthalmology 1986;93:189-193.
Chapter 464
44  Summanen, P, Immonen, I, Kivela, T, Tommila, P, Heikkonen, J, Tarkkanen, A. Radiation related 
complications after ruthenium plaque radiotherapy of uveal melanoma. Br J Ophthalmol 1996;80:732-
739.
45  Egger, E, Schalenbourg, A, Zografos, L, et al. Maximizing local tumor control and survival after proton 
beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys 2001;51:138-147.
46  Harbour, JW, Char, DH, Kroll, S, Quivey, JM, Castro, J. Metastatic risk for distinct patterns of postirradiation 
local recurrence of posterior uveal melanoma. Ophthalmology 1997;104:1785-1792; discussion 1792-
1783.
47  Niederkorn, JY. Enucleation in consort with immunologic impairment promotes metastasis of 
intraocular melanomas in mice. Invest Ophthalmol Vis Sci 1984;25:1080-1086.
48  Puusaari, I, Heikkonen, J, Summanen, P, Tarkkanen, A, Kivela, T. Iodine brachytherapy as an alternative 
to enucleation for large uveal melanomas. Ophthalmology 2003;110:2223-2234.
49  Vrabec, TR, Augsburger, JJ, Gamel, JW, Brady, LW, Hernandez, C, Woodleigh, R. Impact of local tumor 
relapse on patient survival after cobalt 60 plaque radiotherapy. Ophthalmology 1991;98:984-988.
50  The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year 
mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006;124:1684-1693.
51  Bedikian, AY, Legha, SS, Mavligit, G, et al. Treatment of uveal melanoma metastatic to the liver: a review 
of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995;76:1665-1670.
52  Diener-West, M, Earle, JD, Fine, SL, et al. The COMS randomized trial of iodine 125 brachytherapy for 
choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001;119:969-
982.
53  Eskelin, S, Pyrhonen, S, Hahka-Kemppinen, M, Tuomaala, S, Kivela, T. A prognostic model and staging 
for metastatic uveal melanoma. Cancer 2003;97:465-475.
54  Kath, R, Hayungs, J, Bornfeld, N, Sauerwein, W, Hoffken, K, Seeber, S. Prognosis and treatment of 
disseminated uveal melanoma. Cancer 1993;72:2219-2223.
55  Kodjikian, L, Grange, JD, Baldo, S, Baillif, S, Garweg, JG, Rivoire, M. Prognostic factors of liver metastases 
from uveal melanoma. Graefes Arch Clin Exp Ophthalmol 2005;243:985-993.
56  Rajpal, S, Moore, R, Karakousis, CP. Survival in metastatic ocular melanoma. Cancer 1983;52:334-336.
57  Rietschel, P, Panageas, KS, Hanlon, C, Patel, A, Abramson, DH, Chapman, PB. Variates of survival in 
metastatic uveal melanoma. J Clin Oncol 2005;23:8076-8080.
65
Karin Muller, M.D.1*, Peter J.C.M. Nowak, M.D., Ph.D.1, Nicole Naus, M.D., Ph.D.2 , 
Connie de Pan1, Cornelis A. van Santen2, Peter Levendag, M.D., Ph.D.1, 
Gré P.M. Luyten, M.D., Ph.D.3
Departments of Radiation-Oncology1 and Ophthalmology2, 
Erasmus Medical Center, Rotterdam, and department of Ophthalmology, 
LUMC, Leiden, The Netherlands
International Journal of Radiation Oncology, Biology and Physics 2009;74(2):497-502
Chapter 566
Abstract
Purpose
To find a dose volume effect for (inhomogeneous) irradiated lacrimal glands.
Methods and Materials
Between 1999 and 2006, 72 patients (42 male, 30 female) were treated with fractionated 
stereotactic radiation therapy in a prospective, nonrandomized clinical trial (median FU 
of 32 months). A total dose of 50 Gy was given on 5 consecutive days. The mean of all 
Schirmer test results obtained six and more months after treatment, was correlated 
with the radiation dose delivered to the lacrimal gland; also, the appearance of dry eye 
syndrome (DES) was related to the lacrimal gland dose distribution.
Results
Seventeen patients developed a late Schirmer value below 10 mm; 9 patients 
developed DES. There was a statistically significant relationship between the received 
median dose in the lacrimal gland versus reduced tear production (p=0.000) and the 
appearance of DES (p=0.003), respectively. A median dose of 7 Gy/fraction to the 
lacrimal gland caused a 50 percent chance of low Schirmer results; a median dose of 10 
Gy a 50 percent probability of DES.
Conclusions
There is a clear dose volume relationship of irradiated lacrimal glands with regard to 
reduced tear production and the appearance of DES.
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Introduction
The lacrimal gland is the main tear secretor of the eye and contributes in particular 
to the production of the middle aqueous layer of a tear film 1. This aqueous layer 
plays an important role in the lubrication of the eye: It supplies oxygen to the corneal 
epithelium, prevents infections, abolishes irregularities of the cornea and removes 
debris from the conjunctiva and cornea 2. If the lacrimal gland is affected by radiation, 
a dry eye syndrome (DES) can occur 3-7. Irradiation of the lacrimal gland can result, after 
a latent period of approximately 6 months, in chronic inflammation and eventually in 
fibrosis and atrophy. 3, 6, 7, 13. Finally, at a dose level of ≥ 40 Gy when applied to the whole 
organ, that is the orbit, a clear dose effect relationship has been established 3-7, 12, 14-25. 
Some of the new 3-D computer-planning systems enable one to apply very conformal 
dose distributions. Therewith, in case of orbital tumors, the critical surrounding normal 
tissues such as the lacrimal gland can be (partly) spared. 
The purpose of this study is to investigate whether a dose volume relationship exists 
and consequently, a dose constraint can be established for the lacrimal gland.
Methods and Materials
Patient characteristics and tumor data
Between 1999 and 2006, 72 uveal melanoma patients (42 male, 30 female) were treated 
with fractionated stereotactic radiation therapy (fSRT), consecutively in a prospective 
one-center clinical trial in order to study the local tumor control, side effects and 
melanoma-related death. All patients signed an informed consent for irradiation in this 
trial.
During the clinical trial nine patients developed DES. Because of the development 
of DES in few patients, Schirmer tests (ColorBar™, Eagle Vision, US) were included in 
the routine ophthalmologic investigations, one year after the initiation of the clinical 
trial. For our analysis we compared the patients with DES versus no DES and also the 
patients with low Schirmer results versus normal Schirmer results to the dose delivered 
in the lacrimal gland. The patient demographics are summarized Table 1.
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table 1  General Data and Tumor Characteristics
total (n=72) no deS (n=63) deS (n=9)
Mean (range) n Mean (range) n Mean (range) n p value
Age (years) 62 (28-82) 62 (28-81) 62 (38-82) 0.96
Gender 0.15
Male 42 39 3
Female 30 24 6
Size (mm)
Diameter
Horizontal 11.5 (7.5-18.9) 11.5 (7.5-18.9) 11.9 (8.4-16.0) 0.53
Vertical 10.1 (6.5-14.9) 9.9 (6.5-14.9) 10.9 (6.5-14.6) 0.60
Prominence 6.1 (2.2-10.9) 6.1 (2.2-10.9) 6.5 (3.4-8.2) 0.24
Schirmer (mm)
pre-treatment 21 (5-35) 21 (5-35) 25 (10-35) 0.60
acute 21 (5-35) 19 (5-35) 21 (10-28) 0.99
late 18 (3-35) 22 (3-35) 6.6 (5-9) 0.00
<10 mm 17 8 9 0.00
Dose in lacrimal gland 
(cGy/fraction)
326 (7-1005) 284 (7-1005) 612 (201-962) 0.00
Follow-up (months) 32 (6-74) 31 (6-74) 34 (13-59) 0.66
Radiation
A total dose of 50 Gy in 5 fractions was delivered on 5 consecutive days. The dose 
was prescribed to the 80% isodose surface, encompassing the planning target volume 
(PTV). There was no dose prescription for the lacrimal gland. More details about the 
treatment are described in former articles 8, 9.
Follow-up
Patients were examined at 3, 6 and 12 weeks after completion of irradiation, followed 
by a three-monthly evaluation during the first year; thereafter the examinations were 
every four months. The median follow-up was 32 months (6 - 74). No patients were lost 
to follow-up. All patients were asked for their symptoms and keratitis was examined 
using a slit lamp. In case of keratitis or dry eye complaints, fluorescein staining was used 
to asses the tear film break-up time and punctuate keratitis. Of all patients Schirmer 
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tests (ColorBar™, Eagle Vision, US) were performed on both the affected and the 
contralateral eye before treatment (51 patients) and at each follow-up appointment. 
A Schirmer strip was inserted into the temporolateral side of the lower fornix without 
anesthesia and was measured after 5 minutes. A mean of the values of 3, 6 and 12 
weeks and 3 months was taken as the acute Schirmer value; the mean of the results of 
6 months and later was considered to be the late Schirmer value.
Analysis
Definitions
Toxicity scores
The common terminology criteria for adverse events (CTCAE, version 3.0) were used to 
describe both the frequency and severity of DES and keratitis 11. Also, RTOG (Radiation 
Toxicity Oncology Group) acute radiation morbidity scoring criteria and the RTOG/
EORTC late radiation morbidity scoring scheme were used to grade radiation-keratitis 
from no (grade 0) to severe (grade 3) keratitis (http://www.rtog.org/members/toxicity/
late.html)10.
Schirmer
The mean of the measurements of the Schirmer was calculated for both acute and late 
values as described above. A mean result of 10 millimeters (mm) or less after 5 minutes 
was considered as reduced. Because it took 6 months for the Schirmer results to drop, 
only the late values were used for the analysis (figure 1).
Dose calculation
Of all patients the maximum dose (D5), the median dose (D50) and the minimum dose 
(D95) delivered in the lacrimal gland, respectively, were calculated. Also, the mean 
radiation dose to the lacrimal gland of each patient was determined.
Statistics
To analyze the relationship between the risk on DES and low Schirmer results versus 
dose delivered in the lacrimal gland , logistic regression analyses were performed. A P 
value of less than 0.05 was considered to be significant.
Chapter 570
FigUre 1  Course of Schirmer during time of FU
Mean Schirmer test results as a function of time of FU; The black line represents the mean 
Schirmer test results of the entire patient population over time; the striped and dotted lines 
represent the course of the Schirmer test results during follow-up of patients with DES and no 
DES, respectively.
Results
Schirmer
Seventeen patients had late Schirmer values below 10 mm, of which 3 had Schirmer 
results of less then 10 mm before treatment. Seven patients did not undergo a pre-
treatment Schirmer test. The remainder developed decreased Schirmer test results 
after 6 to 9 months of FU. The change in the Schirmer test result over time is shown in 
Figure 1.
Eight patients with low late Schirmer test results had no complaints of dry eye.
Symptoms
After a minimum of 6 months of FU, 9 patients developed complaints due to DES, which 
arose 3 to 6 months after therapy (with only one exception of 24 months; Table 2).
All patients with complaints of dry eye had low late Schirmer test results.
The location of the tumors with regard to the lacrimal glands for patients with DES and 
no DES is illustrated in Figure 2.
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table 2  Side effects
grade (Number of patients)
0 1 2 3 4
RTOG
Acute 61 7 3 0
Late 64 2 3 3
CTC
Dry eye 62 3 3 4
Keratitis 61 6 3 2 0
FigUre 2  Position of the tumors with regard to the lacrimal gland
Schematic view of location of the tumors with regard to the eye; the positions are divided into 9 
subgroups: Nasal, central and temporal located tumors and cranial, central and caudal located 
tumors. The numbers represented are the absolute numbers of patients with DES within that 
relative compartment (between brackets: total number of patients within relative compartment).
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Endpoints
Schirmer versus dose in lacrimal gland
There was a statistically significant relationship between a late Schirmer test result of 
less than 10 mm versus the mean dose (p=0.001) and the D5 (p=0.000), D50 (p=0.000) 
and D95 (p=0.001) delivered in the lacrimal gland, respectively.
A mean dose of the lacrimal gland of 6 Gy/fraction and a median dose of 7 G/fraction 
caused a reduced tear production in 50 percent of the cases (i.e. TD50; Figure 3).
FigUre 3  Graphs of logistic regression analyses of Schirmer test results versus dose in lacrimal 
gland
The y-axis represents the Schirmer test result: 0 for Schirmer >= 10, 1 for Schirmer < 10; on the 
x-axis the dose delivered in the lacrimal gland is pointed out; each cross and circle represents a 
patient; the drawn line depicts the chance on a Schirmer result of <=10 versus the dose.
a. Schirmer test results versus median dose in lacrimal gland (cGy). 
b. Schirmer test results versus minimum dose (D95) in lacrimal gland (cGy). 
 
   
a. b.
c. Schirmer test results versus mean dose (D50) in lacrimal gland (cGy). 
d. Schirmer test results versus maximum dose (D95) in lacrimal gland (cGy). 
   
c. d.
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DES versus dose in lacrimal gland
Patients with DES received a significantly higher mean (p=0.003), minimum (p=0.005), 
median (p=0.003) and maximum (=0.003) dose in the lacrimal gland compared to 
patients with no DES. 
According to Figure 4, a mean dose of 8 Gy/fraction and a median dose of 10 Gy/
fraction was associated with a 50% probability of DES (TD50).
FigUre 4  Graphs of logistic regression analyses of DES versus dose in lacrimal gland.
The y-axis represents the appearance of DES: 0 is no DES, 1 is DES; on the x-axis the dose in the 
lacrimal gland is pointed out; each cross and circle represents a patient; the drawn line depicts 
the chance on DES versus the dose in the lacrimal gland.
a. DES versus median dose in lacrimal gland (cGy). 
b. DES versus minimum dose (D95) in lacrimal gland (cGy). 
   
a. b.
c. DES versus mean dose (D50) in lacrimal gland (cGy). 
d. DES versus maximum dose (D95) in lacrimal gland (cGy). 
  
c. d.
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Discussion
The main lacrimal gland is the exocrine orbital gland and plays a dominant role in 
the aqueous tear secretory system 1. Dysfunction of this gland results in DES, with 
serious complaints such as uncomfortable itchy eyes, foreign body sensation and 
photophobia 2. Orbital irradiation can result in decreased tear production due to the 
integral dose received by the lacrimal gland 3-7. With regard to DES, a clear dose effect 
relationship has been reported in the literature for whole orbit irradiation 3-7, 12, 14-25. 
However, current radiation techniques, such as stereotactic irradiation and intensity 
modulated radiation therapy (IMRT), can tailor the dose more precisely to the planning 
target volume (PTV), therewith sparing the lacrimal gland. Given the fact that many 
of the departments of radiation oncology now routinely use 3D- treatment planning 
systems (3D-TPS) we found it to be of interest to study the dose effect relationship for 
the lacrimal gland in more detail. 
The aim of the current research was to obtain the normal tissue complication probability 
(NTCP) for the non-uniformly irradiated lacrimal gland. Regarding the NTCP, the model 
of Lymann-Kutcher 26-32 is frequently cited. The non-universal outcome, however, reflects 
to a certain extend that this model is based on a number of assumptions. Moreover, in 
order to fit our data into the model, our irradiation schedule of 5 fractions of 10 Gy had 
to be “translated” into a 2 Gy/fraction model, which again complicates the applicability 
of the Lymann-Kutcher model 31, 33. In this paper, for simplicity reasons it was elected to 
calculate a median threshold dose.
Figure 4 represents the dose effect relationship for DES in case of irradiation of the 
lacrimal gland; a median threshold dose of 10 Gy/fraction can be observed (TD50). It is 
of interest that even at a relatively low dose, a number of patients apparently complain 
of dry eye syndrome. However, if the tumors were located in the nasal and/or inferior 
part of the globe, no DES was found (figure 2).
Besides the dose-related dry eye syndrome, it is important to realize that according 
to literature some systemic diseases and drugs, such as beta-blockers and diuretics, 
are also associated with DES. For the study population of this paper, affected patients 
were screened for relevant systemic co-morbidity and medication 36, 37, 42-44. That is, of 
the 9 patients 4 were found with hypertension 34-37, 2 with hypercholesterolemia and 1 
with diabetes 37-41. However, in the affected patients with systemic disease and/ or drug 
use, Schirmer test results before treatment and of the contralateral eye were excellent. 
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Therefore, there was no indication for possible blending of side effects and thus, DES 
seems to be related to dose only.
The diagnosis of dry eye, is hampered by the lack of sufficient discriminatory diagnostic 
tests 45, 46, especially in mild cases. Although the Schirmer test is one of the most 
valuable tests to measure the (aqueous) tear production, the uncertainty of the cut-off 
value and its (daily) fluctuations are important limitations 41, 45, 47, 48. We elected a cut-off 
point of 10 mm to eliminate false negative results. A mean value was used to diminish 
the variation. 
In this study, all patients with DES had low Schirmer results. Moreover, low Schirmer 
values were associated with significantly higher doses to the lacrimal gland (figure 
3). However, half of the patients (8) with altered low late Schirmer results had no 
complaints of DES. It is well known that DES is multifactorial; even without radiation 
damage to the lacrimal gland, patients can still develop DES symptoms e.g. because 
of an unstable tear film being the result of radiation damage to Goblet cells in the 
conjunctiva and the small glands in the eyelid, structures supplying the fatty layer in 
the tear film 1, 2. 
Other possible disturbing factors for the outcome of the Schirmer test are age 37, 41, 42, 49 
(although this is not universal 50-52) and female gender 36, 37, 41, 42, 50, 52, 53. Both factors were 
equally distributed between the DES- and no DES groups.
Obviously, our study has its shortcomings. First, we started with Schirmer test one year 
after the initiation of the SRT trial of uveal melanoma, with as most important raison 
the incidence of DES and KS in a few patients. As a clear consequence, the pretreatment 
Schirmer results of these patients are lacking. Fortunately, we could draw on the values 
of the contralateral eyes.
Furthermore, although a respectable group of treated patients, the number of patients 
with DES is rather small. To draw conclusions out of such a small group contains a 
certain risk. On the contrary, the differences of both groups (with and without DES) 
were considerable and despite the small number of DES patients a clear relationship 
between the appearance of DES and the mean dose received in the lacrimal gland 
could be established. Moreover, since we started to spare the lacrimal glands, we were 
able to reduce the number of DES in nearby located tumors considerably.
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Conclusion
DES due to irradiation occurs rarely in fSRT of uveal melanoma. When novel irradiation 
(sparing) techniques are used (as is the case in fSRT), sparing of the lacrimal gland is 
feasible. In our study, a clear dose/volume relationship with regard to the appearance 
of DES and tear production was found. 
However, for a dry eye to be associated with significant complaints (DES) one needs to 
appreciate that the DES is a multifactorial process. This is exemplified by the fact that 
in our study population half of the patients with a low tear production do not complain 
of DES.
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Abstract
Purpose
To compare survival and secondary enucleation rate of patients with choroidal 
melanoma treated with Ruthenium-106 brachytherapy (Ru-106) versus stereotactic 
radiotherapy (SRT).
Methods and materials
We included patients treated for medium size choroidal melanoma with either Ru-106 
or SRT in the Leiden University Medical Center (LUMC) and the Erasmus Medical Center 
(EMC) from January 2000 till December 2007 with a tumor prominence between 2 and 
8 mm. In order to obtain comparability between patients treated with Ru-106 and 
patients treated with SRT, all records were abstracted uniformly to make it impossible to 
identify patient and treatment center. Ophthalmologists from LUMC and EMC assessed 
these anonymous charts to indicate their treatment preference. Patients were assumed 
to be prognostically interchangeable when a different preference was expressed (one 
physician selecting Ru-106, the other SRT). The original treatment of these patients 
was used for a retrospective comparison of outcomes. Primary endpoints were overall 
survival (OS), metastatic-free survival (MFS) and secondary enucleation.
Results
228 patients treated with Ru-106 and 39 patients treated with SRT were selected 
according to this analysis based on prognostic interchangeability. 5-year OS of the 
patients treated with Ru-106 was 76,6% and 77.4% for the SRT group (p=0.37). 5-year 
MFS was 80.3% and 82.3%, respectively (p=0.59). 9.6% of the Ru-106 group and 15.4% 
of the SRT group underwent enucleation (p=0.36), in the Ru-106 group the mainly due 
to local recurrence (55%); in the SRT group mainly due to toxicity (67%).
Conclusion
No significant differences were found in survival and secondary enucleations for 
patients treated with Ru-106 compared with SRT.
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Introduction
Choroidal melanomas are treated differently depending on size, prominence and 
availability of treatment modalities. Various eye sparing treatment modalities have 
been developed during the last decades. For small and medium sized choroidal 
melanomas, plaque brachytherapy (using Ruthenium-106 or Iodine-125) has proven to 
be effective in avoiding enucleation 1-7. The use of brachytherapy is however limited to 
a maximum tumor prominence. For (medium to) large sized melanomas external beam 
radiation techniques have been developed 8-21. At Leiden University Medical Center 
(LUMC) choroidal melanomas with a maximum prominence of 8 mm are treated with 
brachytherapy using a Ruthenium-106 applicator (Ru-106) 22-24. In 1999, stereotactic 
radiotherapy (SRT) was introduced at Erasmus University Medical Center for treatment 
of melanomas up to a prominence of 12 mm 19,25. A substantial proportion of the 
medium sized choroidal melanomas could thus be treated with either of both radiation 
methods. The main goal of our study was to determine the differences in clinical and 
survival outcomes after Ru-106 and SRT, respectively, for choroidal melanomas of 
comparable size. 
Methods and Materials 
Patient selection
We analyzed all choroidal melanomas with a prominence of 2 to 8 mm diagnosed in 
LUMC and EMC between January 2000 and December 2007 and treated either with 
Ru-106, SRT or enucleation, or were sent to a center for proton beam radiation in (PSI, 
Villigen, Switzerland). For measuring tumor prominence ultrasound B-scans were used. 
Patients were excluded when metastases were present at diagnosis, or when patients 
had received treatment elsewhere before.
In this retrospective study we wanted to make both patient groups treated with Ru-
106 and SRT comparable. For this we used an analysis based on expressed physician 
preference by the mathematical statistician Edward L. Korn 26. In order to achieve 
comparability, all patient charts were depersonalized with regard to personal 
information, treatment center, treatment and results . From both LUMC and EMC an 
experienced ophthalmologist was consulted to assess these anonymous patient charts 
Chapter 684
and express their preference on how to treat each patient/melanoma. Both appraisers 
could choose one from all treatment options available: enucleation, ruthenium-106 
brachytherapy, stereotactic radiotherapy and proton beam radiation.
The tumors that were preferred to be treated with enucleation or proton beam radiation 
by one or both ophthalmologists were excluded, leaving patients with melanomas 
that were judged prognostically interchangeable: there was no strong indication for 
on specific treatment modality, and these tumors could have been treated with either 
Ru-106 and SRT, depending on the preference of the physician. When both appraisers 
preferred the same treatment (either both Ru-106 or SRT), the tumor was excluded. The 
original treatment of the final study group was used for a retrospective comparison of 
outcomes.
An ophthalmologist specialized in ocular melanomas used to work in EMC and 
transferred to LUMC in 2006. To prevent bias, we excluded this person in assessing the 
anonymous patient charts.
Treatment 
Brachytherapy at LUMC was performed using Ruthenium-106 applicators manufactured 
by Bebig (Echet & Ziegler Eckert & Ziegler BEBIG GmbH, Berlin, Germany). Doses of 400 
to 600 Gy combined with transpupillar thermotherapy (TTT), or 600 to 800 Gy without 
TTT were given. The dose was prescribed at the scleral surface and standardized to a 
dose of 100 Gy per 24h by using a correction factor 22. For treatments after Jan 1, 2008, 
the dose was specified at the maximum prominence (130 Gy), and TTT was only used 
for insufficient regression.
Stereotactic radiotherapy at EMC was given on a linear accelerator with a stereotactic 
immobilization device. A treatment plan was made using stereotactic arcs of 6 MV 
photons (Xknife RT™ 1.03 Radionics). A total dose of 50 Gy was delivered in 5 fractions 
on 5 consecutive days. Treatment details have been described in previous publications 
19,25,27.
Statistics
Primary endpoints were overall survival (OS) and metastatic-free survival (MFS) after 5 
years, and percentage of secondary enucleations.
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We used the Kaplan Meier to analyze survival. The survival outcomes were compared 
using Log Rank tests. For the comparison of the enucleation data the Chi Square test 
was used.
FigUre 1  Diagram of patient selection
Results
The initial patient group, after excluding all enucleation and proton beam radiation 
treated patients, consisted of 371 patients treated with Ru-106 and 68 with SRT. After 
limiting the analysis to patients for whom a different preference was expressed, 228 
Ru-106 patients (105 female, 123 male) and 39 SRT patients (21 female, 18 male) were 
included in the study (Figure 1). Median age was 62 years for the Ru-106 group and 
66 for the SRT group; median tumor diameter was 11.5 mm and 11.1 mm, and median 
tumor prominence was 4.6 mm and 5.1 mm for the patients treated with Ru-106 and 
SRT, respectively (Table 1). 
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table 1  General Data and Tumor Characteristics
characteristics ru-106
Median (range) na
     Srt
Median (range) nb
p
Age (years) 62 (29-83) 66 (48-83) 0.11
Gender 0.37
Male 123 18
Female 105 21
Follow-up (months) 63 (9-120) 51 (7-116) 0.02
Size (mm)
Diameter 11.5 (6.7-15.5) 11.1 (7.7-15.6) 0.35
Tumor thickness 4.6 (2.5-7.9) 5.1 (3.2-7.6) 0.04
a  Total number of patients is 228
b  Total number of patients is 39
The 5-year OS showed no significant difference between the Ru-106 and the SRT groups: 
76.6% versus 77.4% (p=0.37, Figure 2), nor did the 5-year MFS: 80.3% versus 82.3% for 
Ru-106 and SRT, respectively (p=0.59, Figure 3). Twenty-two patients (9.6%) treated 
with Ru-106 were enucleated versus 6 patients (15.4%) treated with SRT (p=0.36). The 
reasons for enucleation are listed in Table 2. For patients treated with Ru-106 local 
recurrences were the most frequent reason for enucleation, while this was toxicity for 
patients treated with SRT. 
FigUre 2  Kaplan Meier curve of overall  FigUre 3  Kaplan Meier curve of metastatic
                       survival                          free survival
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table 2  Causes of Enucleation
description ru-106 Srt 
Local recurrence 12 2
Toxicity 6 4
Unknown 4
Total a 22 6
a Absolute number of patients
Discussion
Brachytherapy with Ruthenium-106 applicators and stereotactic radiotherapy have 
both been developed to treat choroidal melanomas while preserving the eye both 
cosmetically and functionally. Indications for both treatment modalities overlap; in this 
study both modalities were compared. 
We found no differences concerning the 5 year overall and metastatic free survival rates 
between Ru-106 and SRT. Our survival outcomes correspond well to known literature. 
In the COMS trial, the 5-year OS was 81% after treatment with I-125 brachytherapy; the 
metastastic rate was 10% after 5 years and 21% after 12 years 2,7. Others reported 5-year 
OS rates of 77-88% for brachytherapy 5,6,28-30 and 82% for stereotactic radiotherapy 20. 
5-year MFS rates vary from 83% to 91% for brachytherapy and from 74% to 80% for SRT 
5,12,31.
It should be noted, however, that the follow-up time of the patients treated with SRT 
was substantially shorter than for those treated with Ru-106. Moreover, metastases 
from choroidal melanomas can develop rather late 7,32,33. Therefore, a subsequent 
analysis is planned after a few more years to determine differences in long-term 
outcome between these two treatments.
In our series, the rates of enucleation were not significantly different between the Ru-
106 and the SRT groups, although numbers were small and a trend for more enucleations 
in the SRT group was found. Brachytherapy is known to be effective, with long-term 
tumor recurrence rates varying from 4 to 15% 3,6,34-36 22. A previous analysis from our 
group showed a satisfactory low recurrence rate of 4%, with 96% eye preservation 22. 
For SRT, data are similar (91-98% local control), but published data have shorter FU 16,19-
21. However, these numbers are small and median follow-up is relatively short. Longer 
follow-up will provide more accurate information on outcomes after SRT. The most 
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important cause of enucleation differed, for Ru-106 this was local recurrence (5% of 
all Ru-106 patients), while for SRT this was toxicity (10% of SRT patients). However, 
these numbers are too small to draw firm conclusions. In future, with more patients and 
longer FU we will establish final comparisons of the rates of preserved visual acuity, 
complications and enucleations. 
It is difficult to compare the results between these treatment modalities (Ru-106 and 
SRT) to literature data, because comparative studies of brachytherapy versus SRT 
have not been published previously, except for one abstract 37. Moreover, virtually 
all published data are based on retrospective studies. In order to achieve the best 
comparability between both patient groups retrospectively, we used an analysis based 
on expressed physician preference 26. 
Conclusion
With a new analysis method based on expressed physician preference, we have been 
able to compare patient groups treated with Ru-106 and with SRT in a retrospective 
manner. No significant differences were found in 5y-OS, 5y-MFS and rates of secondary 
enucleations for patients treated with Ru-106 compared with SRT. A second analysis is 
planned after longer follow-up, to determine the differences in MFS, side effects and 
visual acuity after treatment. 
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Summary
Uveal melanomas can develop in any part of the uveal tract, but mostly they arise 
in the choroidea (1). Traditionally, uveal melanomas are treated by enucleation of 
the affected eye. During the last decades, various eye sparing treatment modalities 
have been developed. Depending on tumor location, size and patient characteristics 
the optimal treatment modality can be selected. For large sized melanomas, external 
beam radiation therapy with photons or heavy particles is being introduced in clinic 
(2-8). Treatment with external beam radiation therapy is complicated since the 
adjacent critical structures in and around the eye are more sensitive to irradiation than 
melanomas. The use of photon irradiation was first published in 1987 (9), presenting 
treatment by a single fraction using a stereotactic device (radio surgery). Although the 
local control rate was good, a substantial number of patients developed serious side 
effects, with the most important disadvantage of radiosurgery being the loss of sparing 
if critical structures are adjacent to the tumor, resulting in an enhanced complication 
probability. Fractionated stereotactic radiotherapy (fSRT) allows for delivery of an 
equivalent effective dose to the tumor combined with reduced effective dose in the 
surrounding tissues.However, fractionating the dose requires a noninvasive relocatable 
frame.
In this thesis, the development and feasibility of fSRT with a relocatable stereotactic 
frame is described. Also, the clinical outcome of fractionated SRT of uveal melanomas 
is reported. In 1999, a longitudinal cohort study was initiated in our institute, in order 
to study both the efficacy and the safety of fSRT for choroideal melanomas. A total dose 
of 50 Gy in 5 fractions (on 5 consecutive days) was given on a LINAC with a stereotactic 
device.
In chapter 2 the development, feasibility and reliability of a patient friendly eye fixation 
device, attached on relocatable stereotactic frame is described. A plastic (PVC™) eye 
fixation construction, containing a blinking light and a camera, was attached to the Gill 
Thomass Cosman frame (GTC frame™, Radionics, Burlington, USA). The blinking light 
(fibre-glass connected to an LED) is positioned in front of the healthy eye. The camera is 
positioned at a distance of 20 cm from the affected eye to verify its position by checking 
the circumference of the eye contours and iris. In order to analyse the repositioning 
accuracy (RA), 2 CT scans were performed of each patient, with the affected eye in 
treatment position: one planning CT scan (before treatment) and a second CT scan 
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after completion of the therapy. The translations and rotations of the affected eye 
balls were calculated. Nineteen irradiated eye melanoma patients were analyzed. The 
average translations of the affected eyes were 0.1 +/- 0.3 mm, 0.1 +/- 0.4, and 0.1 +/- 
0.5 mm, respectively. The median rotation of the diseased eye was 8.3 degrees. These 
movements are all within the applied margin of 2 mm from the target volume (GTV) 
to the planning treatment volume (PTV). It can be therefore concluded that the eye 
fixation device is an adequate and reliable system for eye melanoma patients treated 
with a relocatable stereotactic frame.
The early effectiveness and acute side effects of fSRT in uveal melanomas are studied in 
chapter 3. In this prospective, nonrandomized clinical trial 38 patients were analyzed. 
Primary endpoints were local control, best corrected visual acuity (BCVA) and acute 
toxicity. The mean follow-up (FU) was 25 months (10-36 months). During this FU, no 
recurrences were seen. The BCVA declined from a mean of 0.21 at diagnosis to 0.06 two 
years after therapy. After an initial decline, the BCVA in most anterior located tumors 
recovered. The BCVA found in the posterior located tumors however was permanent. 
The most common acute side effects were mild conjunctival symptoms, loss of hair or 
lashes and fatigue. One patient underwent an enucleation 2 months after irradiation, 
because of total retinal detachment and massive inflammation. In conclusion, fSRT of 
uveal melanoma was well tolerated and resulted in excellent local control. The BCVA 
two years after therapy was however disappointing, mainly because of the considerable 
tumor size and the location of tumor. Obviously, larger number of patients and a 
prolonged FU were needed for long-term local control, late toxicity and survival.
In chapter 4 long term local control, late side effects and survival are evaluated. The 
clinical outcome of 102 patients were analyzed; the median FU was 32 months. Local 
control was achieved in 96% of the patients; 4 patients had to be enucleated due to 
local tumor progression after a median FU of 40 months (14-85 months). Because of 
failure of downsizing of the tumor, 6 patients underwent transpupillar thermotherapy. 
Ten patients developed cataract grade 3; the development of cataract turned out 
to be dose dependent: a median dose of 5 Gy/fraction in the lens and ciliary body 
caused a cataract in 50 percent of the cases. Severe retinopathy and opticoneuropathy 
grade 3 or 4 occurred in 19 and 13 patients, respectively. For opticoneuropathy a dose 
dependency was found (TD50 of maximum dose in the optical nerve was 9.6 Gy/
fraction). Before therapy, 57 patients had retinal detachment (RD). Eventually, 2 years 
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post-treatment, RD resolved in all patients, but 2: These 2 patients who developed 
RD grade 4, had to be enucleated (1 because of secondary endophthalmitis after 
vitrectomy). Larger melanomas and the existence of grade 2 or 3 RD before treatment 
appeared to be prognostic predicting factors for the development of grade 3 and 4 RD. 
Eight patients out of 9 who developed grade 3 or 4 neovascular glaucoma (NVG) had 
to be enucleated. Tumor thickness and the appearance of grade 3 retinopathy were 
predicting factors for the development of NVG. Sixteen patients died, corresponding 
to a 5-year overall survival (OS) of 77% (SE 6%); the 5-year melanoma-specific survival 
(MSS) rate was 83% (SE = 5%). Fourteen patients developed distant metastases (5-year 
MFS 75%). In all cases the liver was affected. In total, 15 patients were enucleated, 2 
to 85 months after radiation, which leads to a 5-year enucleation-free survival of 66%.
The radiosensitivity of the lacrimal gland in uveal melanoma patients is pointed out in 
chapter 5. The goal of this paper was to find a dose volume effect for (inhomogeneous) 
irradiated lacrimal glands. For this purpose, the development of a dry eye syndrome 
(DES) and the course of tear production of 72 irradiated patients were analyzed and 
related to the dose in the lacrimal glands. We found a dose volume relationship of 
irradiated lacrimal glands with regard to the appearance of DES and to reduced tear 
production. A median dose of 7 Gy/fraction to the lacrimal gland caused a 50 percent 
chance of low Schirmer results; a median dose of 10 Gy corresponded to a 50 percent 
probability of DES. In conclusion, there is a clear dose volume relationship of irradiated 
lacrimal glands with regard to reduced tear production and the appearance of DES.
In conclusion, fSRT is an efficient and safe treatment modality for uveal melanomas. 
However, the visual acuity after treatment is disappointing and the number of 
secondary enucleations is substantial. It is known that clinical outcome of treatment of 
uveal melanomas is depended on tumor and patient characteristics. This complicates 
the comparison of our data to literature. It is therefore of interest to compare our data 
with equal tumor and patient characteristics treated with other eye sparing modalities 
(and enucleation). In chapter 6 the data of patients with medium sized tumors (i.e. 
2-8 mm) treated with fSRT (68 patients) in the Erasmus MC were compared to patients 
with similar characteristics treated with ruthenium brachytherapy (371 patients) in 
LUMC (Leiden). The comparison was achieved according to a retrospectively performed 
intention to treat analysis. After the intention to treat analysis, 367 patients (228 Ru, 39 
fSRT) were suitable for the comparison. No significant differences were found in overall 
survival, metastatic-free survival and secondary enucleation rate.
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Future perspectives
Tumor definition
For the sake of both better organ sparing and higher local tumor control, an excellent 
tumor definition is warranted. In some cases, the delineation of the tumor on the 
planning CT and MRI was difficult, due to the position of the tumor (i.e. cranially or 
caudally in the globe) and/ or the unclear demarcation of the tumor. Uveal melanomas 
are best visualized on ultrasonography. The development and implementation of 
software that matches images of 3D sonography with the planning CT scan could fix 
this problem for a major part. The matching of the MRI with the CT scan was often 
complicated because of the different gaze directions in both scans. Besides, the eye 
globe was sometimes substantially deformed. This problem could be (partly) solved 
with an MRI compatible eye fixation device, which is currently under development. 
Also, the technique of the MRI can be improved (10, 11).
Toxicity
The outcome of visual acuity was disappointing, especially in posterior located tumors. 
Also, the number of enucleations due to toxicity was substantial.
The most important reason for enucleation is the occurrence of NVG. Hopefully, if we 
can get a better comprehension in the pathophysiology and development of NVG, we 
can reduce it. 
Comparison of treatment modalities
Like ours, published data of treatment of uveal melanomas are mostly nonrandomized 
small clinical trials (2, 4, 7, 8, 12-23). It is of interest to compare our data set with 
similar tumor and patient characteristics treated with other eye sparing modalities 
and/or enucleation. We performed an analysis in which patients treated with fSRT 
had comparable results in survival and secondary enucleations with respect to similar 
patients treated with brachytherapy. Comparison of local control, toxicity and visual 
acuity of these groups will be executed in near future.
Also, planning studies using different treatment modalities should be performed in 
order to analyze the best treatment option for various melanoma sizes and locations 
(24).
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Treatment developments
Future research should be aimed to improve the existing treatment techniques and 
to prolong the FU of new treatment techniques with as ultimate goal the reduction 
of treatment related morbidity and the improvement of local tumor control and 
functional outcome (25). 
Another explanation for local tumor failure could be the variability in intrinsic radiation 
sensitivity of uveal melanomas (26-28). With a better understanding of the radiation 
sensitivity it is probably possible to identify the group of patients that benefits of 
radiation.
Quality of life
Since enucleation and eye sparing treatment modalities have comparable survival 
results, improvement of the quality of life (QoL) should be an important goal in eye 
sparing treatment modalities. Especially with the substantial number of secondary 
enucleations and the disappointing results in BCVA, the QoL after treatment with fSRT is 
of major importance. For brachytherapy, published papers showed no large differences 
in quality of life, patients treated with brachytherapy are more vital and have slightly 
better visual results but were also more anxious when compared to patients treated 
with enucleation (29-33). All uveal melanoma patients treated between 1999 and 2008 
at the Erasmus MC (with fSRT or enucleation) filled in QoL questionnaires. These data 
will be analyzed and reported in the near future.
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Samenvatting
Oogmelanomen kunnen zich in ieder onderdeel van de tractus uvealis ontwikkelen, 
maar ze komen het meest frequent in de choroidea voor (1). Van oudsheris enucleatie 
van het aangedane oog de behandeling voor oogmelanomen. In de afgelopen 
decennia zijn er echter verschillende oogsparende behandelmodaliteiten ontwikkeld. 
Afhankelijk van de tumorlocatie, de tumorgrootte en de patiëntenkenmerken kan de 
meest optimale behandeling worden gekozen. Voor grote tumoren is er uitwendige 
radiotherapie met fotonen dan wel zware partikels (2-8). Behandeling met uitwendige 
radiotherapie is een uitdaging omdat de aangrenzende kritieke structuren in en om 
het oog gevoeliger zijn voor bestraling dan het oogmelanoom zelf. Het onderzoek 
zoals beschreven in dit proefschrift heeft zich gericht op uitwendige radiotherapie met 
fotonen. De behandeling middels uitwendige radiotherapie met fotonen is voor het eerst 
gepubliceerd in 1987 (9). In deze publicatie werd een behandeling met radiochirurgie 
beschreven. Hierbij werd een eenmalige dosis gegeven met behulp van een 
stereotactisch bestralingsapparaat. Alhoewel de lokale controle goed was, ontwikkelde 
een substantieel deel van de patiënten ernstige bijwerkingen. Het belangrijkste 
nadeel van de radiochirurgie is de relatief hoge (eenmalige) bestralingsdosis die in de 
aangrenzende kritieke structuren wordt afgegeven. Dit resulteert in een groter risico 
op complicaties. Met behulp van gefractioneerde stereotactische radiotherapie (fSRT) 
kan de bestralingsdosis in delen gegeven worden. Hiermee kan de tumor met een 
equivalent effectieve dosis worden bestraald, terwijl de aanliggende structuren beter 
kunnen worden gespaard. Echter, als de dosis in meerdere fracties wordt gegeven is 
een niet-invasief en herbruikbaar bestralingsframe vereist.
In dit proefschrift wordt de ontwikkeling en de haalbaarheid van fSRT met een niet-
invasief en herbruikbaar stereotactisch frame beschreven. Daarnaast worden de 
klinische resultaten van de behandeling met fSRT voor oogmelanomen gerapporteerd. 
In 1999 werd er in het Erasmus MC een longitudinale cohortstudie gestart om de 
werkzaamheid en de veiligheid van een behandeling met fSRT voor oogmelanomen te 
onderzoeken. Hierbij werd er een dosis van 50 Gy gegeven, verdeeld in 5 fracties van 
10 Gy (op 5 achtereenvolgende dagen). De bestraling werd gegeven op een lineaire 
versneller speciaal geschikt voor stereotactische radiotherapie.
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In hoofdstuk 2 wordt de ontwikkeling, haalbaarheid en betrouwbaarheid van een 
patiëntvriendelijk oogfixatiesysteem, wat bevestigd kan worden aan een bestaand 
herbruikbaar stereotactisch frame beschreven. Het onderzoek is als volgt gedaan: een 
plastic (PVC™) oogfixatieconstruktie, bestaande uit een knipperend lampje en een 
camera, werd bevestigd aan het Gill Thomass Cosman frame (GTC frame™, Radionics, 
Burlington, USA). Het lampje (fiberglas met een LED) wordt voor het gezonde 
oog geplaatst. De camera bevindt zich 20 cm voor het aangedane oog en filmt het 
aangedane oog. Door de oogcontouren en de contour van de iris te controleren, wordt 
de positie van het aangedane oog geverifieerd.
De herpositioneringsnauwkeurigheid werd geanalyseerd met behulp van een 2-tal 
CT-scans van iedere patiënt. Hierbij was het oog in de behandelpositie: één CT-scan 
werd gemaakt voorafgaand aan de behandeling en ten behoeve van de planning. De 
tweede scan werd na de behandeling gemaakt. De behaalde resultaten waren als volgt: 
van 19 bestraalde oogmelanoompatiënten werden de verplaatsingen en rotaties van 
de aangedane ogen berekend en geanalyseerd. De gemiddelde verplaatsingen van 
de aangedane ogen waren respectievelijk 0.1 +/- 0.3 mm, 0.1 +/- 0.4, en 0.1 +/- 0.5 
mm. De mediane rotatie van het zieke oog was 8.3 graden. Deze verschuivingen waren 
allemaal binnen de toegepaste marge van 2 mm rondom het doelvolume (GTV) naar 
het ‘planning treatment volume’ (PTV). Hiermee kan worden geconcludeerd dat het 
oogfixatiesysteem een adequaat en betrouwbaar systeem is voor de fSRT-behandeling 
van oogmelanomen. 
De vroege resultaten en de acute bijwerkingen van fSRT voor oogmelanomen zijn 
beschreven in hoofdstuk 3. In deze prospectieve, niet-gerandomiseerde klinische trial 
werden 38 patiënten geanalyseerd. De primaire eindpunten waren lokale controle, de 
gecorrigeerde visus (‘best corrected visual acuity’ (BCVA)) en de acute toxiciteit. De 
gemiddelde follow-up (FU) was 25 maanden (10-36 maanden). Tijdens deze FU werden 
er geen lokale recidieven gezien. The BCVA nam af van een gemiddelde van 0.21 
gemeten bij de diagnose naar 0.06 twee jaar na de behandeling. Bij de meeste anterior 
gelegen tumoren herstelde de BCVA zich enigszins. Bij de posterior gelegen tumoren 
was de afname in BCVA permanent. De meest voorkomende acute bijwerkingen waren 
milde symptomen van de conjunctiva, verlies van haar of wimpers en vermoeidheid. 
Bij één patiënt werd het aangedane oog 2 maanden na de bestraling geënucleëerd, 
omdat er sprake was van een totale netvliesloslating in combinatie met een uitgebreide 
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ontstekingsreactie. Concluderend werd de behandeling met fSRT voor oogmelanomen 
goed getolereerd en was de lokale controle na een korte FU uitstekend. De BCVA was 
na 2 jaar FU echter teleurstellend. Voor lokale controle op lange termijn, late toxiciteit 
en overleving zijn grotere patiëntenaantallen en een langere FU nodig .
In hoofdstuk 4 worden de lokale controle op lange termijn, de late toxiciteit en de 
overleving beschreven. Hiervoor werd de klinische uitkomst van 102 patiënten 
geanalyseerd; de mediane FU van deze groep was 32 maanden. Bij 96% van de 
patiënten werd lokale controle van het oogmelanoom bereikt; 4 patiënten moesten, 
na een mediane FU van 40 maanden (14-85 maanden), worden geënucleëerd vanwege 
lokale tumorprogressie. Zes patiënten ondergingen transpupillaire thermotherapie, 
omdat de tumor niet snel genoeg in grootte afnam. Tien patiënten ontwikkelden een 
graad 3 cataract. Het ontstaan van cataract bleek uit onze analyse dosisafhankelijk te 
zijn: wanneer er een mediane dosis van 5 Gy/fractie in de lens en het corpus ciliare 
kwam, veroorzaakte dat in 50% van de patiënten een cataract. Ernstige retinopathie 
en opticoneuropathie graad 3 en 4 trad op bij respectievelijk 19 en 13 patiënten. Ook 
de kans op het optreden van ernstige opticoneurpathie was afhankelijk van de dosis 
(TD50 van de maximum dosis in de n opticus was 9.6 Gy/fractie). Bij de diagnose van het 
oogmelanoom hadden 57 patiënten een ablatio retinae. Twee jaar na de behandeling 
was deze ablatio bij alle patiënten hersteld, met uitzondering van 2 patiënten met een 
graad 4 ablatio retinae, die allebei een enucleatie ondergingen (1 van deze 2 patiënten 
onderging een enucleatie vanwege een secundaire endophthalmitis na vitrectomie). 
Prognostisch voorspellende factoren voor de kans op de ontwikkeling van een graad 
3 of 4 ablatio retinae waren de grootte van de tumor (grotere tumoren gaven een 
grotere kans) en de aanwezigheid van graad 2 of 3 ablatio retinae bij diagnose. Van de 9 
patiënten die een graad 3 of 4 neovasculair glaucoom (NVG) ontwikkelden, moesten er 
uiteindelijk 8 een enucleatie ondergaan. Voorspellende factoren voor het ontwikkelen 
van NVG waren de tumordikte en het optreden van graad 3 retinopathie.
Er overleden 16 patiënten, wat overeenkomt met een 5-jaars overleving van 77% (SE 
6%); de 5-jaars melanoomspecifieke overleving (MSS) was 83% (SE = 5%). Veertien 
patiënten kregen afstandsmetastasen (5-jaars metastasenvrije overleving van 75%). Bij 
alle 14 was ook de lever aangedaan. In totaal werd bij 15 patiënten het aangedane oog 
geënucleëerd, variërend van 2 tot 85 maanden na de radiotherapie, overeenkomstig 
met een 5-jaars enucleatievrije overleving van 66%.
Samenvatting en toekomstperspectief 103
De stralingsgevoeligheid van de traanklier bij oogmelanoompatiënten wordt 
beschreven in hoofdstuk 5. Het doel van het onderzoek, dat beschreven is in dit artikel, 
was om een dosis-volume effect te vinden voor (inhomogeen) bestraalde traanklieren. 
Hiervoor werden zowel het optreden van droge ogen (dry eye syndrome (DES)) als het 
verloop van de traanproduktie van 72 bestraalde patiënten geanalyseerd. Er werd een 
dosis-volume verband gevonden ten aanzien van zowel de kans op het krijgen van 
DES als op de afname van de traanproduktie en de dosis in de traanklier. Een mediane 
dosis van 7 Gy/fractie gegeven aan de traanklier veroorzaakte een kans van 50 procent 
op verminderde traanproduktie; een mediane dosis van 10 Gy correspondeerde met 
een kans van 50% op het krijgen van DES. Concluderend was er een duidelijke dosis-
effect-relatie tussen de dosis die de traanklier had gekregen versus de verminderende 
traanproduktie en het optreden van DES.
Uit de bovenstaande hoofdstukken kan geconcludeerd worden dat fSRT een efficiënte 
en veilige behandeling is voor oogmelanomen. De visus na behandeling is echter 
teleurstellend en ook het aantal secundaire enucleaties is substantieel. De klinische 
uitkomst van de behandeling van oogmelanomen is afhankelijk van zowel tumor- 
als patiënteneigenschappen. Dit compliceert het vergelijken van onze data met de 
bestaande literatuur. Het zou interessant zijn om onze data te kunnen vergelijken met 
andere oogsparende behandelingsmodaliteiten (en enucleatie) met vergelijkbare 
tumor- en patiëntenkarakteristieken. In hoofdstuk 6 werd de data van 68 patiënten 
met oogmelanomen van een gemiddelde grootte (i.e. 2-8 mm), die behandeld zijn met 
fSRT in het Erasmus MC (Rotterdam) vergeleken met 371 vergelijkbare patiënten, die 
behandeld zijn met ruthenium brachytherapie (Ru) patiënten in het LUMC (Leiden). De 
groepen werden vergeleken met behulp van een retrospectief uitgevoerde ‘intention-
to-treat’ analyse. Na deze analyse waren er 367 patiënten (39 fSRT, 228 Ru) geschikt 
voor de vergelijking van beide behandelingen. Hierbij werd er geen verschil gevonden 
in de overleving (overall survival en metastastic-free survival) noch in de aantallen 
secundaire enucleaties. 
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Tumordefinitie
Zowel voor betere sparing van de gezonde weefsels als voor betere lokale tumorcontrole 
is een uitstekende afbeelding van de tumor noodzakelijk. Intekening van de tumor op 
de plannings-CT-scan en de gematchte MRI-scan werd soms bemoeilijkt door de ligging 
van de tumor (i.e. craniaal of caudaal in de oogbol gelegen tumoren) en/of door de 
matige afgrensbaarheid van de tumor. Oogmelanomen zijn het best zichtbaar op een 
ECHO. De ontwikkeling en implementatie van software die de 3D ECHO-afbeeldingen 
kan matchen met de CT-scan kan een groot deel van dit intekenprobleem oplossen. 
De matching van de MRI- met de CT-scan werd bemoeilijkt doordat de kijkrichting van 
de beide scans verschilde. Daarnaast was de oogbol op de MRI in sommige gevallen 
substantieel vervormd. Door een oogfixatiesysteem te gebruiken dat ook geschikt is 
voor de MRI zou een deel van het probleem kunnen worden opgelost. Dit systeem is 
momenteel in ontwikkeling. Verder kan de techniek van de MRI worden verbeterd (10, 
11).
Toxiciteit
De uitkomst van de visus was teleurstellend, vooral voor de posterior gelegen tumor. 
Bovendien was het aantal enucleaties dat verricht moest worden ten gevolge van de 
toxiciteit substantieel. De belangrijkste reden voor deze enucleaties was het optreden 
van NVG. Hopelijk krijgen we in de toekomst meer inzicht in de pathofysiologie en in 
de ontwikkeling van NVG, zodat we dit kunnen verbeteren. 
Vergelijking van de behandelingsmodalitieiten
Net zoals onze data, zijn de meeste publicaties over de behandeling van oogmelanomen 
niet-gerandomiseerde kleine klinische trials (2, 4, 7, 8, 12-23). Het zou interessant 
zijn om onze uitkomsten van fSRT voor oogmelanomen te kunnen vergelijken met 
patiënten met vergelijkbare tumor- en patiëntkarakteristieken die behandeld zijn 
met andere oogsparende behandelmodaliteiten en/of enucleatie. We hebben een 
vergelijkende analyse uitgevoerd, waarbij bij patiënten die behandeld zijn met fSRT en 
met brachytherapie vergelijkbare resultaten waren te zien ten aanzien van overleving 
en secundaire enucleatie. Binnenkort zullen lokale controle, toxiciteit en visus van beide 
groepen met elkaar vergeleken worden. Bovendien zullen planningsstudies, waarbij 
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de verschillende bestralingsmodaliteiten met elkaar vergeleken worden, ons meer 
duidelijkheid moeten geven over de meest optimale behandeloptie voor verschillende 
tumorafmetingen en –locaties (24).
Ontwikkeling van nieuwe behandelingen
Toekomstig onderzoek moet gericht zijn op het verbeteren van de bestaande 
behandelingstechnieken met als doel het verminderen van behandelingsgerelateerde 
morbiditeit en het verbeteren van de lokale tumorcontrole en de functionele uitkomst 
(25). Bovendien is er een langere FU nodig van de patiënten die behandeld zijn met 
nieuwe behandelingstechnieken. Een andere verklaring voor het falen van lokale 
tumorcontrole zou de variabiliteit in intrinsieke radiosensitiviteit van oogmelanomen 
kunnen zijn (26-28). Door een beter begrip van de radiosensitiviteit is het wellicht 
mogelijk om patiëntengroepen te kunnen identificeren die gevoelig zijn voor 
radiotherapie.
Kwaliteit van Leven
Aangezien enucleatie en oogsparende behandeltechnieken vergelijkbare 
overlevingsresultaten hebben, zou verbetering van de Kwaliteit van Leven (KvL) een 
belangrijk doel moeten zijn voor (nieuwe) oogsparende technieken. Het relatief grote 
aantal secundaire enucleaties en de teleurstellende resultaten in de BCVA, maakt 
onderzoek naar de KvL na behandeling met fSRT nog belangrijker. Publicaties over 
KvL na brachytherapie lieten geen grote verschillen zien. Patiënten behandeld met 
brachytherapie zijn vitaler en hebben iets betere visusresultaten, maar waren ook 
angstiger vergeleken met patiënten die behandeld waren met enucleatie (29-33). 
Alle oogmelanoompatiënten die behandeld zijn tussen 1999 en 2008 in het Erasmus 
MC (met fSRT of enucleatie) hebben KvL- vragenlijsten ingevuld. Deze data zullen 
binnenkort worden geanalyseerd en gepubliceerd. 
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